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ABSTRACT 
 
Background: Mast cells (MCs) are granule containing immune cells with varied 
functions in both health and disease. Mas-related gene X2 (MrgX2) expressed on 
human but not mouse MCs functions as a binding site for a wide variety of 
biologically relevant cationic peptides including human beta defensins (hBDs), 
LL-37, eosinophil-derived major basic protein (MBP) and substance P (SP) 
leading to degranulation. Atopic dermatitis is a cutaneous inflammatory disease 
that involves MCs, eosinophils and the neuropeptide SP. Rosacea is a chronic 
inflammatory cutaneous disease, which involves dysregulation of LL-37 and MCs 
and is associated with neurogenic inflammation mediated by neuropeptides such 
as SP. MCs, hBDs and LL-37 are involved in the pathogenesis of chronic 
periodontitis. Increased numbers of MCs are present in the bronchial smooth 
muscles of patients with asthma. Furthermore, neutrophils and eosinophils play 
important roles in the last phase of allergic asthma. However, possible roles of 
MrgX2 on host defense and inflammatory diseases have not been determined. 
 
Objectives: We sought to determine if human skin, gingiva and lung MCs 
express MrgX2 and to test if its expression is upregulated in atopic dermatitis, 
rosacea, chronic periodontitis and asthma. We investigated the localization of 
MrgX2 before and after stimulation with a known ligand cortistatin and finally we 
tested the feasibility of utilizing humanized mice as a model for in vivo functional 
studies on MrgX2. 
 
Methods: We analyzed skin samples from 3 patients with atopic dermatitis, 2 
patients with rosacea and 3 control subjects. For the study on chronic 
periodontitis, we analyzed gingiva tissue from 3 patients with chronic periodontitis 
and 1 control subject. Lung tissue samples from 6 patients who died of asthma 
related complications and 6 control subjects that died of other causes as well as 
humanized mice lung tissue were also analyzed. Immunohistochemical analysis 
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was used to determine the presence of MCs in relation to structural cells in the 
tissues. Immunofluorescence double-staining method was used to detect the 
expression of MrgX2 by MCs. RBL-2H3 cells transiently expressing MrgX2 were 
used to investigate receptor localization. 
 
Results: MCs in healthy and diseased skin, gingiva and lungs express MrgX2. 
The expression of MrgX2 was not significantly different in the skin of patients 
diagnosed with atopic dermatitis and rosacea compared with control subjects. 
We did not quantitate the expression of MrgX2 in chronic periodontitis due to 
limited sample size, however MCs in gingiva of chronic periodontitis patients 
express MrgX2. There was a significant increase in MCs, MrgX2-positive cells as 
well as MrgX2-positive MCs in asthmatic lung tissue compared with healthy lung 
tissue. Using RBL-2H3 cells, we found that MrgX2 was expressed on the plasma 
membrane as well as intracellularly and on stimulation, we found evidence of 
possible mobilization of the receptor. Finally, we found that human MCs, which 
develop in the lungs of humanized mice, express MrgX2. 
 
Conclusions: Expression of MrgX2 by MCs in healthy skin, gingiva and lung 
suggests that it plays an important role in host defense by enabling crosstalk 
between MCs, hBDs expressed by epithelial cells and LL-37 expressed by 
neutrophils. Our finding that MCs that express MrgX2 are upregulated in chronic 
asthma suggests it participates in the pathogenesis of asthma. Given that hBD3, 
LL-37 and eosinophil-derived peptides are increased in periodontits, rosacea and 
AD, respectively suggest that MrgX2 contributes to these diseases via increased 
MC degranulation.  Finally, humanized mice may be used as models for future in 
vivo studies on the role of MrgX2 in human disease conditions.  
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1. INTRODUCTION 
 
1.1 Mast cells 
1.1.1. Biology of Mast cells 
Mast cells (MCs) are multifunctional immune cells that are derived from 
hematopoietic stem cells (HSCs) in the bone marrow but differentiate locally in 
the tissues (1, 2). MCs are present in almost all vascularized tissue, being more 
abundant at sites that are exposed to external pathogens and allergens such as 
the skin and the mucosal surfaces of the gastro-intestinal and respiratory tracts 
(3, 4). They are usually found under the epithelium residing in the connective 
tissue adjacent to blood vessels and in close proximity to nerve fibers (4-8). The 
growth, development and maturation of MCs are regulated by the c-kit ligand, 
stem cell factor (SCF) as well as other factors including nerve growth factor, 
neurotrophin-3, IL-3 and the Th2 associated cytokines IL-4 and IL-9 (9, 10). 
 
Human MCs are classified into two subtypes based on the composition of their 
secretory granules. Thus, MCT, predominantly express tryptase while MCTC 
express both tryptase and chymase (11). MCTC are more prominent in skin and 
intestinal submucosa while MCT are more prominent in the lung alveolar wall and 
intestinal mucosa (12). Mouse MCs are classified into connective tissue type 
MCs (CTMCs) and mucosal MCs (MMCs). However, MCs are heterogenous and 
changes in subtypes can be modulated by environmental factors and differences 
in stimuli (3, 13). 
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Upon activation, MCs release a diverse range of potent inflammatory mediators 
which can be classified into (1) pre-formed mediators including histamine, 
serotonin, renin and proteases such as tryptase, chymase and 
carboxypeptidase-A (2) newly synthesized lipid mediators such as leukotrienes, 
prostaglandins and (3) chemokines, growth factors and cytokines including tumor 
necrosis factor (TNF), IL-4, IL-5, IL-6, IL-13, macrophage chemotactic protein-1 
(MCP-1), platelet-derived growth factor (PDGF), vascular endothelial-derived 
growth factor (VEDGF), transforming growth factor (TGF) and fibroblast growth 
factor (FGF) (2, 4, 8, 9).   
 
1.1.2. Functions of MCs  
The role of MCs in allergy and anaphylaxis has been extensively studied (8, 14, 
15). However, MCs play an important role in inflammatory and autoimmune 
conditions, as well as in host defense against various pathogens including 
parasites, bacteria and viruses (16, 17). Because of their ubiquitous location in 
vascularized tissue, MCs are one of the first immune cells to interact with 
environmental antigens and pathogens (4). They also play a pivotal role in 
maintaining a healthy physiology by promoting innate immunity, angiogenesis 
and wound healing (18, 19). MCs are involved in regulating the differentiation of 
naïve T-cells, the development of B cells, as well as the migration, recruitment 
and activation of dendritic cells, T-cells, neutrophils, eosinophils and monocytes 
(20-22). MC-derived histamine and proteases potently induce vasodilatation and 
vascular permeability, which enhances the migration of leucocytes to sites of 
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inflammation, infection and tissue repair (2, 10). Other MC mediators such as 
leukotrienes, proteases and cytokines also act as chemotactic signals for 
neutrophils, basophils and eosinophils (23).  
 
MCs also promote the initiation and generation of the adaptive immune response 
by expressing both major histocompatibility complex (MHC) class I and class II 
proteins via which they present antigens to T cells (24-26). 
 
1.1.3. MCs and Antimicrobial peptides 
Antimicrobial peptides (AMPs) such as defensins and cathelicidins are small 
positively charged amphipathic molecules, which are crucial in the clearance of 
microbial pathogens and thus play an important role in host defense. They 
interact with negatively charged phospholipid moieties on microbes resulting in 
membrane destabilization, disruption and killing of the offending pathogen (27). 
In addition to their anti-microbial properties, AMPs also modulate the immune 
system, angiogenesis and wound healing (28-30). In humans, defensins are 
characterized into α and β-defensin families depending on the position of 
cysteine residues that are involved in disulphide linkages (31). α-defensins are 
produced by polymorphonuclear leucocytes and intestinal paneth cells while 
human β- defensins (hBDs) are produced primarily by epithelial cells (30). Of the 
four members of the hBD family that have been characterized in detail (hBD1-4), 
hBD1 is expressed constitutively, while the rest are induced by bacteria, viruses 
and cytokines (32). LL-37 is produced by leucocytes as an inactive precursor 
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(hCAP18), which is enzymatically cleaved to release the active LL-37. Its gene 
expression is induced by infection, inflammation and 1,25-dihydroxyvitamin D3 
(33).  
MCs interact with AMPs. Both hBDs and LL-37 induce Ca2+ mobilization, 
chemotaxis and degranulation in MCs (34-37). Niyonsaba et al showed that 
epithelial cell derived hBD2 acts as a chemo-attractant for MCs (38). The same 
group also showed that in addition to its anti-microbial properties, LL-37 induces 
MC chemotaxis thereby participating in their recruitment to sites of inflammation 
(39). MC degranulation mediated by these AMPs results in the release of 
mediators such as histamine, which causes vasodilation and increased vascular 
permeability resulting in the recruitment of leucocytes and immune cells 
necessary for combating the microbial pathogens (40). 
 
1.1.4. MCs and the nervous system 
MCs are localized near nerve endings at several anatomical sites such as the 
skin, lungs, intestinal mucosa and central nervous system. They interact with 
neurons in a bi-directional manner to affect various physiological functions such 
as wound healing and stress response (41, 42). Histamine, serotonin and 
tryptase released from MCs have an impact on the activity of sensory neurons, 
and conversely, MCs are activated by neuropeptides such as calcitonin gene-
related peptide (CGRP) and substance P (SP) released by nerve terminals of 
sensory neurons (43). 
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The neuropeptide SP, released from nerve terminals in the central and peripheral 
nervous system has a key function in stress response, neurogenic inflammation 
and pain (43, 44). Human MCs have been shown to degranulate and release 
mediators in response to SP (45-47). Other neuropeptides, which activate MCs 
include vasoactive intestinal polypeptide (VIP) and neuropeptide Y (46, 48, 49). 
 
The skin has a very rich supply of sensory nerve endings, which release SP and 
other neuropeptides leading to MC degranulation in response to the continuous 
exposure to physical as well as emotional stimuli. Therefore, the interaction 
between MC and neuropeptides results in the promotion of MC-driven 
inflammation and granulocyte infiltration (44, 50). 
 
1.1.5. MCs and wound healing 
MCs play pivotal roles in all stages of wound healing: the initial inflammatory 
response, revascularization and re-epithelialization of the damaged tissue, 
deposition of temporary connective tissue and finally remodeling of the matrix 
(23, 51). During wound repair, the MC mediators, histamine, heparin, cytokines 
(TNF, IL-6 and IL-8) and growth factors (PDGF, VEDGF, TGF and FGF) 
modulate the stages of neovascularization thereby contributing to the regrowth of 
the endothelial cells (42, 52). MC mediators histamine, tryptase, TGF and the 
cytokines IL-1, IL-4 and TNF are able to stimulate chemotaxis, migration, 
phenotypic differentiation and activation of fibroblasts (23). MCs can also 
modulate keratinocyte proliferation and migration during the re-epithelialization 
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process of wound healing (53, 54) and at the final stages of the wound healing 
process, MCs influence the structural re-modeling of newly formed capillaries by 
releasing angiogenic factors (55). 
 
1.1.6. MCs and homeostasis   
MCs play a role in the control of tissue remodeling. They are involved in the 
regulation and maintenance of organs that undergo continuous growth and 
structural remodeling such as hair follicles and bones (56). Hair follicle cycling 
through periods of rest and growth is impaired in MC-deficient mice and MC-
derived histamine and TNF have been implicated in regulating hair follicle 
transformation from resting to active hair growth (56, 57). MCs also contribute to 
bone remodeling. The amount of new bone matrix synthesized in MC-deficient 
mice is diminished compared to wild type (WT) mice suggesting that MCs and 
their mediators influence the recruitment of osteoblast and osteoclast progenitors 
during bone remodeling (58). MCs have also been reported to secrete 
osteopontin, a glycoprotein that is involved in immune responses and controls 
bone metabolism (59). 
 
1.1.7. MC activation 
MCs express the high affinity Fc receptor for IgE known as FcεRI on their cell 
surface. During IgE dependent immune responses, activation and degranulation 
of MCs occurs with crosslinking of the high affinity receptor by IgE/antigen 
complexes (3, 9). In addition to IgE mediated degranulation of MCs, multiple non-
 18 
IgE mediated mechanisms are also known to trigger MC secretion including 
activation via the G-protein coupled receptor, Mas-Related Gene X2 (MrgX2) 
expressed on MCs.  
 
1.2 Mas-related gene X2 (MrgX2)  
1.2.1. What is MrgX2? 
The G protein coupled receptors (GPCRs) are one of the largest known family of 
transmembrane proteins. Mas–related G protein coupled receptors (Mrgprs) 
belong to the GPCR family and are divided into several subfamilies. In humans 
four Mrg genes, MrgX1 – MrgX4 are known, while in mice, the Mrg family 
comprises of 32 different Mrg coding genes (60). Mrgprs are also referred to as 
sensory neuron specific GPCRs because they were originally thought to be 
exclusively expressed in dorsal root ganglia (60, 61). However, it has now been 
shown that MrgX2 is expressed in LAD2 (a human MC line) and CD34+ cell 
derived MCs while human cord blood-derived MCs express both MrgX1 and 
MrgX2 (62-64). Also, a higher expression level of MrgX2 mRNA has been 
reported in skin-derived cultured MCs compared to lung-derived cultured MCs 
(65).  
 
From prior studies on MCs, pertussis-sensitive G proteins have been shown to 
be activated by a wide range of endogenous and exogenous polycationic 
molecules collectively known as basic secretagogues (66). Neuropeptides such 
as SP and VIP are basic secretagogues, which play a role in the pathogenesis of 
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chronic urticaria, atopic dermatitis and other inflammatory skin conditions (67, 
68). 
 
MrgX2 has now been shown to function as the non-selective, low-affinity binding 
site for a wide range of basic secretagogues such as SP, cortistatin (CST), 
somatostatin, mast cell degranulating peptide (MCDP), neuropeptide Y, 
compound 48/80 and VIP (62, 64, 69, 70). Although these peptides are 
structurally unrelated, they are all amphipathic small peptides, which induce 
dose-dependent degranulation of human MCs via the activation of MrgX2 with an 
associated increase in the intracellular Ca2+ concentration (64, 70). 
 
Subramanian et al also showed that hBDs and the cathelicidin LL-37 activate 
human MCs via MrgX2 (32, 63). In their study, LL-37 and the neuropeptide CST 
induced sustained Ca2+ mobilization in LAD2 cells and CD34+-cell-derived 
primary human MCs, which are known to endogenously express MrgX2. 
Substantial MC degranulation with associated increased intracellular Ca2+ 
mobilization was induced by hBD2, hBD3 and CST in a rodent MC line, RBL-2H3 
stably expressing MrgX2 (32). Therefore, MrgX2 functions as a non-selective 
binding site that links these basic peptides to G proteins, leading to the secretion 
of histamine and other mediators by MCs (71).  
 
To facilitate in vivo studies on the function, activation and downstream effects of 
MrgX2, it is important to identify the mouse counterpart of the human receptor. 
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There are significant differences between Mrg receptors in different species. 
Human and mouse Mrg receptors share only 45-65% amino acid sequence 
identity making it difficult to determine the mouse orthologue (64). In a study by 
Subramanian et al, they found that degranulation of murine MCs was resistant to 
activation by hBDs while human MCs were susceptible highlighting the possibility 
that there may be differences between the human and murine receptors (32). 
However, in a recent study by McNeil et al, they reported that basic 
secretagogues activated mouse MCs in vitro and in vivo through Mrgbrb2, which 
they concluded to be the mouse counterpart of the human MrgX2 receptor (72). 
 
1.2.2. Receptor localization and internalization 
Receptor desensitization and internalization are key regulatory mechanisms 
involved in GPCR signaling. Activated GPCRs are phosphorylated by a group of 
serine/threonine protein kinases known as G protein coupled receptor kinases 
(GRKs) with subsequent recruitment of β-arrestin. This results in desensitization 
and internalization of the receptors with resultant inhibition of function (73, 74). It 
has been reported that MrgX2 is resistant to agonist-induced receptor 
phosphorylation, desensitization and internalization, which is contrary to 
established reports of the behavior of most GPCRs such as C3aR, the receptor 
for the anaphylatoxin C3a (63, 75). In the study by Subramanian et al., MrgX2 
was relatively resistant to phosphorylation after stimulation with CST and LL-37 
in HEK-293T cells transfected with hemagglutinin (HA)-tagged MrgX2 compared 
to C3aR stimulation with the corresponding ligand, C3a.  Using Ca2+ mobilization 
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assay, they demonstrated that MrgX2 did not undergo desensitization. Instead, 
sustained intracellular Ca2+ mobilization was noted in LAD2 cells after stimulation 
with CST and LL-37. Also, MrgX2 was not internalized in HMC-1 cells stably 
expressing HA-tagged MrgX2 upon stimulation with LL-37 in contrast to C3aR 
(63). 
 
Unlike most GPCRs, MrgX2 is expressed intracellularly. Fujisawa et al reported 
localization of MrgX2 in the cytoplasm of LAD2 cells and in the same study, they 
determined that MrgX2 was expressed intracellularly in human adult peripheral 
blood-derived cultured MCs (65). 
 
1.3 MCs and MrgX2 in disease 
Under healthy conditions, MC numbers are relatively constant. However, in 
inflammatory conditions and infection, their numbers are increased.  
 
1.3.1. Role of MCs and MrgX2 in chronic urticaria 
Chronic urticaria (CU) is defined as the presence of daily hives for at least six 
weeks (76). MCs are involved in the pathogenesis of CU through the release of 
various inflammatory mediators (77, 78). Neuropeptides are also involved in the 
pathogenesis of CU. The neuropeptide SP is upregulated in the serum of 
patients with chronic spontaneous urticaria (79) and a study has shown that 
intradermally injected SP in CU patients led to enhanced and longer lasting 
wheal reactions compared with controls (80). Urticaria is associated with 
 22 
eosinophil infiltration and the deposition of eosinophil-derived major basic protein 
(MBP) (81). Recently, Fujisawa et al. reported that the number and percentage of 
MrgX2 positive MCs is increased in the skin of patients with severe chronic 
urticaria compared with control subjects (65). Since MBP is a cationic peptide, 
which has been reported to activate MCs (82), in the same study by Fujisawa et 
al., they investigated the possibility that MrgX2 is the receptor for MBP and found 
that MBP induced histamine release from human skin MCs through MrgX2 (65). 
Thus, it is likely that MrgX2 expressing MCs are also involved in the 
pathogenesis of other inflammatory disease conditions involving MCs including 
but not limited to atopic dermatitis, rosacea, periodontal disease and asthma. 
 
1.3.2. Role of MCs in atopic dermatitis 
Atopic dermatitis (AD), synonymous with atopic eczema is a chronic 
inflammatory relapsing disease of the skin, which often precedes other allergic 
disorders such as food allergy, asthma and allergic rhinitis (83, 84). It is the result 
of a complex interaction between genetic, immunological and environmental 
factors. The onset of AD is usually in early childhood, most commonly between 3 
and 6 months of age. However a small percentage of patients develop their first 
symptoms in adulthood (85). It affects 15-20% of children and 1-3% of adults 
worldwide (86). 
The diagnosis of AD is based on a constellation of clinical features, which include 
persistent pruritus, age-dependent eczematous eruptions, a chronic relapsing 
course, early age of onset, atopy and xerosis (85). Pruritus is often worse at night 
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resulting in sleep disturbance and impaired quality of life. The cheeks and scalp 
are typically affected in infants, while adolescents and adults usually present with 
lichenified plaques affecting the head, neck and flexures (87). Histologically, AD 
is characterized by spongiosis which is a non-specific histological pattern seen in 
various eczematous reactions.  
There is a genetic predisposition to the development of AD. Approximately 70% 
of AD patients have a positive family history of atopy (88). Also, the rate of AD is 
77% among monozygotic twins compared to 15% in dizygotic twins (89). Loss of 
function mutations in the filaggrin gene that result in dysfunction of the skin 
barrier are strongly associated with AD (90-92). Filaggrin is involved in 
maintaining the epidermal barrier and integrity. Hence filaggrin gene mutations 
result in impairment of the skin barrier function with resultant increase in 
transepidermal water loss and microbial infections (90). AD patients are therefore 
susceptible to colonization and infection with Staphylococcus aureus as well as 
herpes simplex virus (HSV) (93). 
The expression levels of the AMPs, hBD2 and LL-37 are downregulated in AD 
lesions. Both AMPs are involved in the control of microbial infections and are 
very potent against the microbes of interest in AD. In addition, they have 
chemotactic properties that link the innate and adaptive immune responses and 
LL-37 also plays a role in maintaining normal epidermal permeability barrier 
function (94). Therefore in AD, the decreased levels of AMPs amplify the 
susceptibility to infection as well as the barrier dysfunction. 
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In acute lesions of AD, MCs are degranulated but not increased in number. 
However, the number of MCs in chronic AD lesions is significantly increased (95-
98). The increased number of MCs could either be the result of recruitment from 
other sites or the proliferation of resident cells (99). Dense dermal infiltration of 
MCs was noted in an animal model of AD providing more evidence for their role 
in the pathogenesis of AD (100).  
MCs may play a role in the pathogenesis of AD by contributing to Th2 
polarization in skin lesions of AD patients through the production of IL-4 and IL-
13. AD is characterized by an increased Th2 response (101) and MCs are a 
major source of IL-4 and IL-13 in AD (102, 103). Using an animal model, Spergel 
et al showed that IL-4 might play an important role in the inflammation and 
hypertrophy of the skin in AD (104). Other mediators of MC degranulation such 
as histamine and tryptase contribute to the development of pruritus and skin 
barrier defects in AD (90). 
Inflammation induced by neuropeptides, which are released from sensory nerves 
in response to psychological stress as well as other physical stressors is known 
as neurogenic inflammation (105). MCs are able to maintain neurogenic 
inflammation in AD through activation by neuropeptides such as SP released by 
cutaneous nerves. Jarvikallio et al showed that dermal contacts between MCs 
and nerves were increased in number in both lesional and non-lesional skin of 
AD patients compared with normal controls. They also found that SP fibers were 
more frequent in lesional papillary dermis compared to nonlesional in AD (106). 
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On the same note, SP plasma level in AD patients is reportedly higher than in 
controls (107). 
Eosinophilia is present in most patients with AD and correlates with disease 
activity (99). Eosinophil degranulation with significant dermal deposition of 
eosinophil-derived MBP in AD has also been demonstrated and also correlates 
with disease activity (108). Therefore, we hypothesized that MrgX2 is involved in 
the pathogenesis of AD and MCs may be activated by eosinophil-derived MBP 
as well as neuropeptides such as SP via MrgX2 resulting in the release of 
histamine and Th2 cytokines.  
1.3.3. Role of MCs in rosacea 
Rosacea is chronic inflammatory cutaneous disorder, which primarily involves the 
facial skin. It is a relatively common dermatological condition, which according to 
the National Rosacea Society affects approximately 16 million people in the 
United States. It affects women more frequently than men (109) with the onset of 
symptoms usually occurring between 30-50 years of age (110). A genetic 
component has been implicated in the occurrence of rosacea, as there is a 
higher incidence in fair-skinned Caucasians compared to those of other 
ethnicities (111, 112).  
 
The clinical course of rosacea is characterized by intermittent episodes of 
exacerbation followed by remission. Patients present with variable 
symptomatology, which include, non-transient centrofacial erythema, flushing, 
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telangiectasia, stinging, burning sensation, dryness, scaling, papules, pustules, 
phymatous growths and red watery eyes (113, 114). Based on these clinical 
features, rosacea has been classified into four subtypes:  
(a) Erythematotelangiectatic rosacea (ETR) characterized by prolonged flushing, 
persistent erythema and telangiectasia (b) Papulopustular rosacea, which is 
characterized by papules and pustules in addition to the features of ETR (c) 
Phymatous rosacea characterized by skin thickening and irregular nodularities 
mostly affecting the nose and (d) ocular rosacea characterized by watery 
bloodshot eyes, burning and stinging sensation in the eyes (110, 115). Exposure 
to ultraviolet light radiation, stress, extremes of temperature and the consumption 
of hot beverages, alcohol and spicy foods are some of the known triggers for 
rosacea exacerbations (116, 117). 
 
The pathophysiology of rosacea has not been fully elucidated, however it has 
been shown to involve dysregulation of the immune, vascular and nervous 
systems. Expression levels of the AMP LL-37 has been shown to be upregulated 
in patients with rosacea (118, 119). LL-37 has antimicrobial, pro-inflammatory 
and angiogenic properties and is induced in keratinocytes by the activation of the 
Vitamin D pathway via UV light (120). Likewise, in lesional rosacea skin, there is 
increased expression of the epidermal trypsin-like serine protease enzyme, 
kallikerin 5 (KLK5), which is responsible for selectively cleaving the inactive 
precursor protein (hCAP18) to form the biologically active LL-37 (119, 121, 122). 
Also found in rosacea skin are abnormal peptide fragments of both LL-37 and 
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KLK5, which are more pro-inflammatory and differ from those found in healthy 
skin (119). The expression of toll-like receptor 2 (TLR2), which is an innate 
immune system pattern recognition receptor is increased in rosacea. TLR2 is 
possibly activated by environmental factors and structural molecules on microbes 
such a chitin released from Demodex mites, which are commensal mite species 
ubiquitous to human skin. Elevated TLR2 expression in rosacea results in 
increased production of KLK5, which cleaves hCAP18 leading to the production 
of LL-37 (123, 124). Thus LL-37 plays a central role in the pathogenesis of 
rosacea. 
 
MCs have been shown to be involved in the pathogenesis of rosacea. Studies 
have revealed significantly greater number of MCs in rosacea lesions compared 
to non-lesional skin (125, 126). In addition to keratinocytes and neutrophils, LL-
37 is also produced from MCs (127). In a study by Muto et al, MC deficient mice 
did not develop inflammation following LL-37 injection whereas WT mice 
developed rosacea-like inflammation (128). In the same study they also showed 
that activation of MCs by LL-37 led to the secretion of MC proteases. MMP-9 is 
secreted by activated MCs and is upregulated in rosacea (128, 129). MMP-9 
cleaves the precursor of KLK5 into the active form of KLK5 also leading to the 
generation of LL-37. Therefore both LL-37 and MCs play critical roles in the 
pathogenesis of rosacea. 
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Neurogenic inflammation mediated by multiple neuropeptides such as SP, VIP 
and pituitary adenylate cyclase-activating peptide (PACAP) has been associated 
with rosacea flare-ups. MCs release their contents upon activation by 
neuropeptides. In an immunohistochemistry study by Wollina et al, there was a 
denser distribution of the VIP receptor positive cells in rosacea lesions compared 
to controls showing the VIP may contribute to the pathophysiology of rosacea 
(130). Increased expression of SP has also been reported in rosacea lesions 
(131). Likewise, tryptase mRNA expression was significantly increased by 
PACAP stimulation in WT mice compared to MC deficient mice (128). Thus, the 
findings that (a) MC numbers are increased in rosacea (b) expression levels of 
LL-37 is upregulated in rosacea (c) neurogenic inflammation mediated by 
neuropeptides is associated with rosacea flare-ups and (d) both LL-37 and 
neuropeptides are MrgX2 ligands suggest that MrgX2 expressed in MCs 
contribute the pathogenesis of rosacea. However, it is unknown if MrgX2 is 
expressed in skin of rosacea patients.  
 
1.3.4. Role of MCs in periodontal diseases 
The periodontium consists of the gingiva, periodontal ligament, cementum and 
alveolar bone.  Periodontal disease refers to a group of inflammatory conditions 
that affect these structures. Gingivitis is the form of periodontal disease, which 
involves the gingiva and is not associated with destruction of the periodontal 
ligament or alveolar resorption while periodontitis involves destruction of the 
attachment apparatus. Chronic periodontitis (CP) is an infectious disease, which 
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results in progressive attachment and bone loss as a consequence of 
inflammation within the supporting tissues of the teeth. 
   
 Dental plaque is considered the principal etiological factor for periodontal 
disease as a result of colonization of the gingival sulcus by microorganisms 
within the dental plaque, which promote an inflammatory response in the 
periodontal tissues. However, the pathogenesis of periodontal disease involves a 
complex multifactorial interaction between plaque microorganisms and the host 
response.  Various social, behavioral, systemic and genetic factors can modify 
the susceptibility of the host to periodontal disease.  Both inflammatory and 
immunologically mediated pathways are upregulated in the presence of bacterial 
plaque resulting in the production of pro-inflammatory mediators by cells of the 
immune system, which are subsequently responsible for causing the damage 
seen in periodontal disease.  
 
MCs are thought to be involved in the pathogenesis of periodontal disease. 
Studies by Huang et al showed a correlation between MC density, degree of 
degranulation and the severity of human periodontitis (132). Other studies have 
also documented an increase in the number of MCs in the gingiva of patients 
with periodontal disease compared with clinically healthy gingival tissue (133, 
134). Activated MCs release histamine, proteases, cytokines and other 
mediators, which perpetuate the immune response and contribute to the healing 
process as well as the destructive process. 
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The AMPs such as hBDs, which are produced by epithelial cells activate human 
MCs via MrgX2 (32).  A study by Lui J.et al reported significantly higher basal 
hBD3 expression in keratinocytes from periodontitis patients compared with 
healthy controls (135).  LL-37, a cathelicidin derived from neutrophils activates 
human MCs via MrgX2. Expression of LL-37 is increased in gingival crevicular 
fluid of patients with chronic periodontitis compared with healthy subjects (136, 
137). These findings suggest that AMPs may play facilitate the immunological 
response in chronic periodontitis through the activation of MCs via MrgX2. 
However, the possibility that human gingival tissue MCs express MrgX2 has not 
been tested.  
 
1.3.5. Role of MCs in asthma 
Asthma is a multifaceted airway inflammatory disease characterized by 
reversible airflow obstruction, airway inflammation, persistent airway hyper-
responsiveness and airway remodeling which results in recurring incidents of 
wheezing, breathlessness, chest tightness and coughing (138-140). According to 
the Centers for Disease Control and Prevention (CDC), asthma affects 7.3% of 
Americans with the burden of disease resulting in reduced quality of life, 
hospitalizations and deaths. 
The etiology of asthma involves a complex interplay between genetic and 
environmental factors. Allergic or extrinsic asthma, which is the most common 
form of asthma, is triggered by inhaled allergens such as pollen, dust, mites and 
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animal dander. Sensitization occurs upon initial exposure to an allergen and on 
subsequent exposure to the same allergen, the clinical symptoms of asthma 
occur. During sensitization, inhaled allergen is intercepted by dendritic cells, 
which function as antigen presenting cells. The antigen is processed by dendritic 
cells and subsequently presented to antigen-specific T-cells, which secrete 
cytokines that stimulate B cells to undergo class switching to IgE-producing B 
cells. The Fc portion of the circulating IgE then binds to MCs and basophils via 
the high affinity Fc receptor for IgE known as FcεRI on their cell surfaces. Upon 
re-exposure to the sensitizing allergen, activation and degranulation of MCs 
occurs with crosslinking of the high affinity receptor by IgE/antigen complexes 
resulting in the release of inflammatory mediators, which initiate an immediate 
acute phase reaction manifested as bronchospasm (140, 141).  
 MCTC are more prominent in skin while normal human lung MCs are 
predominantly of the MCT phenotype with the minority being MCTC. These MCT 
are found in the alveolar wall and epithelium of the lung while MCTC are 
preferentially located in the bronchial smooth muscles and glandular areas (142). 
However, markedly increased numbers of MCTC are present in the bronchial 
smooth muscles of patients with severe asthma (143-146). It has been shown 
that normal skin MCs which are typically MCTC express GPCRs for MrgX2 while 
normal lung MCs do not express these receptors (147). These findings suggest 
that MrgX2 expressed in asthmatic lung MCTC could participate in the 
pathogenesis of asthma.  
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Human rhinovirus (HRV) and Respiratory syncytial virus (RSV) which exacerbate 
asthma symptoms in children (148) are associated with increased induction of 
hBDs in bronchial epithelial cells (149-152). Therefore, it is possible that these 
hBDs activate MCTC in the bronchial smooth muscles of asthmatic patients via 
MrgX2 leading to the exacerbation of their symptoms. Neutrophils and 
eosinophils are known to play important roles in the late phase of allergic asthma 
(153). Subramanian et al., showed that neutrophil-derived AMP, LL-37 activate 
human MCs via MrgX2 (63). Furthermore, Fujisawa et al. showed that cationic 
peptides released from activated eosinophils cause degranulation in MCTC-type 
MCs via MrgX2 (65). These findings raise the interesting possibility that MrgX2 
expressed in lung MCTC contributes to the pathogenesis /exacerbation of asthma. 
However, it is unknown if human lung MCs express MrgX2 and if their expression 
is modulated during asthma. 
 
1.4 Humanized mice as a model for in vivo studies on MrgX2 
Studies have shown that MrgX2 is activated by small cationic peptides such as 
neuropeptides and AMPs. However, no in vivo functional studies have been 
carried out primarily due to the fact that MrgX2 is not expressed in mice. Also, 
studies by Subramanian et al showed that known MrgX2 ligands do not activate 
murine MCs (32, 63). Therefore, new models need to be developed to study the 
biology of human MrgX2 in vivo.  
 
One of the most exciting recent advances in translational research has been the 
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development and utilization of humanized mice to study the role of human 
lymphoid and myeloid cells in vivo (154-158). It is well documented that the 
receptor for the murine SCF, c-kit is important for the development of murine 
MCs. Kambe et al., (159) provided the first demonstration that engraftment of 
human HSCs, (CD34+ cells) into severely immune deficient mice leads to the 
development of some human MCs in mouse lung and skin indicating that mouse 
endogenous SCF is able to support human MC development to a certain extent. 
However, functional characterization of these MCs has not been performed. 
More recently, a new model has been developed in which an immune-deficient 
mouse (NOD, SCID, IL2 receptor --null; NSG) expresses three transgenes; 
human SCF, GM-CSF and IL-3, each driven by a human cytomegalovirus 
promoter/enhancer and constitutively produce 2 - 4 ng/ml of these human 
cytokines in the serum (NSG-SGM3) (160, 161). Given that SCF and IL-3 are 
important growth factors for human MCs, we predicted that these mice will serve 
as “incubators” for the differentiation of human CD34+ cells into MCs. Therefore 
one of the aims of this study was to do an initial assessment of the feasibility of 
utilizing humanized mice as a model for in vivo functional studies on MrgX2, as 
well as mouse models to determine the role of MrgX2 in human disease 
conditions involving MCs. 
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2. RESEARCH AIMS 
Objectives 
There are three objectives of the present study:  
1) To determine if human skin, gingival and lung MCs express MrgX2 and to test 
if its expression is upregulated in human disease conditions such as AD, 
rosacea, chronic periodontal disease and asthma.  
 
2) To investigate the localization of MrgX2. To determine if the receptor is 
localized to the plasma membrane, cytoplasm or both and to further evaluate if 
the localization changes on stimulation. 
 
3) To test if human MCs that develop in humanized mice express MrgX2. 
 
3. MATERIALS AND METHODS 
3.1 Sample Collection 
The study protocols for the expression of MrgX2 by human skin and gingival 
tissues were approved by the Institutional Review Board (IRB) of the University 
of Pennsylvania. The IRB protocol number for the gingival study is 822486 and 
for the skin study, it is 808225. The gingiva study was conducted using pieces of 
otherwise discarded gum tissue that were removed during the normal course of 
periodontal surgery on patients at the Graduate Periodontics Clinics, School of 
Dental Medicine, University of Pennsylvania. Written informed consent was 
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obtained from all patients prior to collection of the gingiva samples. The 
discarded tissue were collected in an anonymous fashion without any patient 
identifiers and transported to the Department of Pathology in10% formalin where 
they were processed and cut into tissue blocks. Skin samples used in this study 
were archival tissue samples of patients provided by the Penn Skin Disease 
Research Center while the human lung samples were provided by Dr. Reynold 
Panettieri (Airway Biology Program, School of Medicine, University of 
Pennsylvania).  
 
3.2 Materials 
All cell culture reagents were purchased from Invitrogen (Gaithersburg, MD). 
Amaxa transfection kit (Kit V) was purchased from Lonza (Gaithersburg, MD). 
Cortitastin (CST) – 14 was obtained from American Peptide (Vista, CA). LL-37 
was from Anaspec (Freemont, CA) and SP was from American Peptide 
Company (Sunnyvale, CA). Rabbit anti-Mrgx2, catalog #: NB110-75035 was 
purchased from Novus Biologicals (Littleton, CO). Mouse anti-human tryptase, 
catalog #: sc-33676 was purchased from Santa Cruz (Dallas, TX). Anti-HA 
mouse monoclonal antibody, catalog #: 11583816001 was purchased from 
Roche Diagnostics (Mannheim, Germany). Donkey anti-mouse secondary 
antibody, Alexa Fluor 488, catalog #: A21202 was purchased from ThermoFisher 
Scientific (Grand Island, NY). Donkey anti-rabbit secondary antibody, Alexa Fluor 
594, catalog #: A21207 was purchased from ThermoFisher Scientific (Grand 
Island, NY). 4’,6-diamidino-2-phenylindole (DAPI) was obtained from Invitrogen 
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(Grand Island, New York). ProLong Gold antifade reagent was purchased from 
Invitrogen (Grand Island, NY). Target retrieval solution was purchased from Dako 
(Carpinteria, CA). Mouse IgG Vectastain ABC kit, catalog #: PK-4002 was 
purchased from Vector Laboratories (Burlingame, CA). 3,3’-diaminobenzidine 
(DAB) peroxidase substrate kit, catalog #: SK-4100 was purchased from Vector 
Laboratories (Burlingame, CA). 
 
3.3 Methods 
3.3.1. Immunohistochemistry 
Immunohistochemistry (IHC) experiments were performed on human normal and 
diseased skin, gingiva and lung tissue as well as humanized mice lung samples 
to show the presence of MCs in the samples. Diseased tissue samples were 
from patients diagnosed with AD, rosacea, CP and asthma. Tryptase was used 
as the MC marker for all experiments. Tissue samples were fixed in 10% formalin 
for 24 hours and subsequently embedded in paraffin and sectioned to 5 μm 
thickness on charged slides (2 sections per slide). The slides were heated to 
55oC overnight, subsequently deparaffinized in Histoclear and hydrated in a 
series of graded ethanol incubations. Antigen retrieval was performed by heat 
treatment using 1X antigen retrieval solution in a water bath at 95oC for 1hour. 
The slides were placed in a humidified chamber and peroxidase quenching was 
achieved with 0.3% H202 blocking solution for 10 minutes at room temperature 
followed by 2 washes in PBS. The slides were incubated for 1hour at room 
temperature with blocking serum using normal horse serum followed by 
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incubation with primary antibody (anti-human tryptase) at a dilution of 1:750 
overnight at 4oC in a humidified chamber.  For negative control, serum blocking 
reagent was used in place of primary antibody on the first section of all slides. 
The sections were then washed 3 times with PBS/0.1% Tween and incubated 
with diluted secondary antibody, biotinylated horse anti mouse IgG for 30 
minutes at room temperature. Following incubation with secondary antibody, they 
were washed 3 times in PBS/0.1% Tween and incubated for 30 minutes with 
Vectastain ABC reagent. Subsequently, they were washed 3 times in PBS/0.1% 
Tween and incubated in peroxidase substrate solution using DAB peroxidase 
substrate kit until desired color intensity was observed. The slides were rinsed 
under running tap water for 5 minutes, counterstained in Mayer’s hematoxylin 
solution for 30 seconds and rinsed again in running tap water until excess 
solution was removed. Rehydration of the tissue was done using increasing 
graded alcohol series followed by Histoclear solution. The slides were allowed to 
air dry before mounting with Permount mounting medium. Images were captured 
on a Nikon Eclipse microscope with an Olympus digital microscope camera using 
4X, 10X and 20X objectives. 
 
3.3.2. Immunofluorescence  
Tissue Samples 
Immunofluorescence (IF) experiments were performed on the same tissue 
samples as IHC experiments. Tissue preparation, sectioning and 
deparaffinization were performed as described above for IHC.  The tissue 
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samples were subsequently incubated with blocking buffer [5% normal donkey 
serum, 0.3% of Triton X-100 in phosphate buffered saline (PBS)] for 1hour at 
room temperature. Incubation with primary antibody (anti-human tryptase) was 
carried out in antibody dilution buffer (PBS with 1% bovine serum albumin and 
0.3% Triton X-100) overnight at 4oC at a dilution of 1:500. For negative control, 
antibody dilution buffer was used in place of primary antibody on the first section 
of all slides. The sections were then washed 3 times with PBS and incubated 
with secondary antibody, Alexafluor 488-conjugated donkey anti-mouse (1:400) 
in conjunction with DAPI (1:4000) for 1 hour at room temperature in the dark. 
Tissue sections were washed 3 times with PBS and incubated overnight at 4oC 
with anti-human MrgX2 primary antibody at a dilution of 1:500. The sections were 
again washed 3 times with PBS and incubated in the dark at room temperature 
with secondary antibody, Alexa flour 594-conjugated donkey anti-rabbit at a 
dilution of 1:400. The tissues were washed 3 times in PBS and mounted with 
ProLong Gold antifade reagent. Images were captured on a Nikon Eclipse 
microscope with an Olympus digital microscope camera using 20X and 40X 
objectives.  
 
3.3.3. Transfection of RBL-2H3 cells 
RBL-2H3 cells were transfected with plasmids encoding HA-tagged MrgX2 using 
the Amaxa nucleofector device and Amaxa kit V, according to the manufacturer’s 
protocol (32, 62). Following transfection, a proportion of the transfected RBL-2H3 
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cells were stimulated with CST for 5 minutes and used in immunofluorescence 
experiments to evaluate the effect of stimulation on the localization of MrgX2. 
 
Immunofluorescence on RBL-2H3 cells expressing HA-tagged MrgX2 
Stimulated and unstimulated RBL-2H3 cells transiently expressing HA-tagged 
MrgX2 were counted and diluted in PBS. Cytospin slides were labeled and 
prepared by attaching plastic cytospin funnel and slide to cytospin clip. 100μl of 
the diluted cells were pipetted into each section of the cytospin funnel. The slides 
were centrifuged at 450rpm for 5 min, left to air dry, then fixed in 100% ice-cold 
methanol for 10 min, followed by rinsing in PBS. The cells were permeabilized 
with 0.5% saponin in PBS for 10 min, washed 3 times in PBS, blocked with 5% 
donkey serum for 1 hour at room temperature and washed again in 3 changes of 
PBS. The cells were incubated overnight at 4OC with anti-HA mouse monoclonal 
antibody diluted in antibody dilution buffer at a dilution of 1:500. The cells were 
washed 3 times in PBS and incubated with secondary antibody, Alexafluor 488-
conjugated donkey anti mouse (1:400) in conjunction with DAPI (1:4000) for 1 
hour at room temperature in the dark. This was followed by 3 times washing in 
PBS and mounting with ProLong Gold antifade reagent. Images were captured 
on a Nikon Eclipse microscope with an Olympus digital microscope camera using 
20X objective.  
 
 
 
 40 
3.3.4. Degranulation 
RBL-2H3 cells (5 X 104) stably expressing MrgX2 were seeded into 96-well 
plates in a total volume of 50μl HEPES buffer containing 0.1% BSA and exposed 
to the peptides LL-37 and SP at 5μM and 10μM. For total β-hexosaminidase 
release, unstimulated cells were lysed in 50μl of 0.1% Triton X-100. Aliquots 
(20μl) of supernatant or cell lysate were incubated with 20μl of 1mM p-
nitrophenyl-N-acetyl-β-D-glucosamine for 1.5 hours at 370C. Reaction was 
stopped by adding 250μl of a 0.1 M Na2C03/0.1 M NaHC03 buffer and 
absorbance was measured at 405nm (32, 63). 
 
3.3.5. Cell Counting and Analysis 
Expression of MrgX2 by MCs in human skin  
Skin samples from 3 patients diagnosed with AD, 2 patients diagnosed with 
rosacea and 3 control patients were analyzed by IF to evaluate the differences in 
number of skin MCs as well as differences in the expression of MrgX2 by skin 
MCs. Pictures were taken from 5 randomly selected visual fields in each skin 
sample at a magnification of 40X. The image exposure, size and dimensions 
were exactly the same for all analyzed images. MCs were identified using 
tryptase antibody and were stained green. MrgX2 positive cells were red in color. 
The number of MCs and were counted in the 5 visual fields and the average of 
the 5 fields was taken as the final count of MCs for that sample. Differences in 
the expression of MrgX2 by MCs were also evaluated. Intensity of tryptase 
expression by MCs as well as intensity of MrgX2 expression in the same MCs 
 41 
was evaluated using Metamorph image analysis software. Using colocalized 
images, the intensity of the green tryptase staining by MCs as well as red MrgX2 
staining in MrgX2-positive MCs was measured. Image exposure was exactly the 
same for all analyzed images. The intensity values were normalized by the area 
of the MCs and an average intensity value was calculated for each skin sample 
analyzed. 
 
Expression of MrgX2 by MCs in human gingiva 
Gingiva tissue samples from 3 patients diagnosed with CP and 1 control patient 
who did not have CP were evaluated qualitatively for the expression of MrgX2 by 
gingiva MCs due to small sample size. 
 
Expression of MrgX2 by MCs in human lung  
Lung tissue samples from 6 patients who died from complications of asthma and 
6 control subjects who died from other causes were analyzed by IF to evaluate 
the differences in number of lung MCs, MrgX2-expressing cells, as well as 
MrgX2-positive MCs. Pictures were taken from 3 randomly selected visual fields 
in each lung sample at a magnification of 20X. The image size and dimensions 
were exactly the same for all analyzed images. MCs were identified using 
tryptase antibody and were stained green. MrgX2-positive cells were red in color. 
The number of MCs, MrgX2 positive cells, as well as MrgX2-positive MCs was 
counted in the 3 visual fields and the average of the 3 fields was taken as the 
final count for that sample. 
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Expression of MrgX2 in humanized mouse lung MCs 
Immune-deficient mice transgenic for human cytokines (NSG-SGM3) mice (3 -4 
weeks old) were preconditioned with busulfan (Sigma, 30 mg/kg, I.V.) or 
sublethally irradiated (150 cGy). The following day, purified human cord blood-
derived CD34+ cells (2 x 105 cells) were injected via tail vein. After 12 weeks 
mice were euthanized and lung preparations were used for IHC and IF studies to 
determine if human MCs develop in these mice and if they express MrgX2.  
 
3.3.6. Statistical analysis 
GraphPad Prism scientific software was used for statistical analysis. Differences 
in the number of skin MCs as wells as differences in the expression of MrgX2 by 
skin MCs were evaluated by using the unpaired student t-test. Differences in the 
numbers of lung MCs, MrgX2-positive cells and MrgX2-positive MCs in the lungs 
were also evaluated by using the unpaired student t-test. 
 
4. RESULTS 
4.1 Expression of MrgX2 in skin samples of patients with AD and Rosacea.  
AD is an inflammatory disease that involves MCs and eosinophils (96, 108). 
Previous studies have shown that MrgX2 is expression in human skin MCs and 
their activation by eosinophil-derived peptides contributes to the pathogenesis of 
another inflammatory skin disease; CU (65). Our first goal was therefore to 
determine if MCs from patients with AD also express MrgX2. For all studies 
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described here and in the sections below with human tissue samples, we utilized 
two approaches to study MCs and MrgX2. First, we used IHC with an anti-
tryptase antibody in combination with hematoxylin and eosin (H & E) to 
determine the presence of MCs in relation to structural cells in skin. Second, we 
utilized a three-color IF approach to determine the expression of MrgX2 (red), 
MCs (green) in the context of the nucleus (blue).  Using IHC, we found that MCs 
are present in the dermal layers in both healthy (Fig. 1A and B) and diseased 
(Fig. 1C and D) skin tissue compared to the epidermis. Using IF, we found that 
Mrxg2 is expressed in normal and AD skin samples (Fig. 2B and D). 
Furthermore, staining of the same sample with anti-tryptase antibody showed 
that the same cells are MCs. When the MrgX2 and tryptase panels were merged, 
it clearly showed that MCs in normal and AD skin samples express MrgX2. 
However, there was a greater intensity of colocalization in the diseased samples 
compared to the normal samples which could indicate that MrgX2 expression by 
MCs is more active in AD compared to healthy skin  (Fig. 2B and D). Using IF, 
we quantitated the number of MCs and found that the number of MCs (tryptase-
positive green cells) was not significantly different in skin tissues from control 
subjects compared with AD patients (Fig. 3). The intensity of tryptase-positive 
green cells was also not significantly different in skin tissues from control 
subjects compared with AD patients (Fig. 4A). The expression of MrgX2 by 
MrgX2-positive MCs was also evaluated and there was no significant difference 
in the intensity of the red staining by MrgX2-positive MCs between the 2 groups 
(Fig. 4B). Of note is the fact that the control skin samples in this study were taken 
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from scar tissue. MCs play key roles in wound healing. Therefore, it is possible 
that the MCs in the control samples were also increased in number and activity 
resulting in similar results between the two groups. 
 
MCs and LL-37 are key players in the pathogenesis of rosacea (118, 125). 
Neurogenic inflammation is associated with rosacea flare-ups. Prior studies have 
shown that LL-37 and neuropeptides such as SP activate human MCs via MrgX2 
(63, 64). Therefore we sought to determine if MCs from patients diagnosed with 
rosacea express MrgX2. Similar to AD, MCs are present in the dermal layers in 
both healthy (Fig. 5A and B) and diseased (Fig. 5C and D) skin tissue compared 
to the epidermis.  As shown in Fig. 6D, MCs in the skin of rosacea patients 
express MrgX2. There is also a greater intensity of colocalization between green 
cells (MCs) and red cells (MrgX2) in the diseased skin sample (Fig. 6D) 
compared to the normal skin (Fig. 6B) possibly indicating greater activity of 
MrgX2 in MCs in rosacea skin compared to healthy skin. Using IF for 
quantitation, we found that the number of skin MCs was not significantly different 
in skin samples of control subjects compared with rosacea patients (Fig. 7).  
Although there was a significant reduction in the intensity of tryptase-positive 
green cells in skin tissues from rosacea patients compared with controls 
(P=0.0260)  (Fig. 8A), the expression of MrgX2 by tryptase-positive MCs was 
evaluated and there was no significant difference in the intensity of the red 
staining by MrgX2-positive MCs between the 2 groups (Fig. 8B). Tryptase is a 
protease found in MCs, which is released on degranulation. MC degranulation 
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plays a direct role in the pathogenesis of rosacea (115). Taken together, these 
results indicate that although the MC numbers are not significantly different 
between the groups, there is an increased degranulation of MCs in rosacea 
resulting in a significant reduction of the intensity of green tryptase-positive MCs 
in rosacea skin. Furthermore, although the intensity of green tryptase-positive 
MCs is reduced in rosacea, the expression of MrgX2 by MrgX2-positive MCs was 
not significantly different between the groups indicating that there is a higher 
activity of MrgX2 in MCs in rosacea skin compared to healthy skin. 
 
4.2 Expression of MrgX2 in normal gingiva and gingiva from patients with 
CP  
MCs and AMPs are involved in the pathogenesis of periodontal disease (132, 
136). Since AMPs have been shown to activate MCs via MrgX2, we sought to 
determine if MrgX2 is expressed by gingival MCs.  IHC and IF analysis were 
performed on gingiva tissue samples from three patients diagnosed with CP as 
well as a control subject not diagnosed with CP.  On IHC, most MCs were 
observed in the lamina propria and submucosa in both healthy (Fig. 9A and B) 
and diseased (Fig. 9C and D) gingiva tissue compared to the epithelium. 
However, gingiva samples from patients with CP showed increased number of 
MCs in the epithelium compared to the healthy gingiva indicating that MCs 
migrate into the epithelium in disease. With IF, we found that Mrxg2 is expressed 
in healthy and CP gingiva samples (Fig. 10B and D). Furthermore, as shown in 
Fig. 10B and D, MCs are present in the human gingival tissue and these cells 
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express MrgX2. Due to small sample size (3 CP patients and 1 control), we did 
not do a quantitative analysis. However, as noted in the skin samples, there was 
also a more intense colocalization in the CP gingiva compared to normal gingiva. 
 
4.3 Expression of MrgX2 in normal and asthmatic lung  
MCTC are markedly increased in the bronchial smooth muscle during asthma 
(144, 146). IHC and IF analysis were performed on lung tissue from patients who 
died from asthma related complications as well as control samples of lung tissue 
from subjects who died from other causes. IHC was performed on lung tissue 
from both groups using human anti-tryptase antibody. As shown in Fig. 11, more 
MCs are observed in the lung smooth muscle of patients who died from asthma 
complications (Fig. 11C and D) compared with control subjects (Fig. 11A and B). 
  
Although it well established that MCs are present in human lung tissue, it is 
unknown if these cells express MrgX2. Furthermore, outside the dorsal root 
ganglia, MCs are the only cells that have been shown to express MrgX2 (60, 62, 
63). To determine if human lung tissue express MrgX2 and if they are found in 
MCs, IF study was performed using anti-MrgX2 and anti-tryptase antibodies. As 
shown in Fig. 12, MrgX2 (red) and MCs (green) could be detected in normal (Fig. 
12B) and diseased (Fig. 12 D) human lung tissue. Merging of the images 
revealed that these MCs express MrgX2. The number of lung MCs was 
significantly greater in lung tissue from patients who died from asthma 
complications compared with individuals who died from other causes (P= 0.0178) 
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(Fig. 13A). The number of MrgX2- positive cells was also significantly greater in 
lung tissue from patients who died from asthma complications compared with 
control subjects (P= 0.0211) (Fig 13B). Furthermore, there were MrgX2-positive 
cells that were not tryptase-positive MCs as shown in Fig. 12D. There were also 
a few MCs, which were not MrgX2-positive but this was not significant between 
the two groups. Next, we compared the number of MrgX2-positive MCs between 
the groups and found a significant increase in the number of MrgX2-positive MCs 
in lung samples of patients who died of asthma complications compared to 
controls (P= 0.0176) (Fig. 14). These results indicate that MrgX2 is involved in 
the pathogenesis of asthma. 
 
4.4 MrgX2 localization 
Most GPCRs are expressed on the plasma membrane and are internalized after 
stimulation (162). However, it has been reported that MrgX2 is expressed on the 
plasma membrane as well as intracellularly (65). Furthermore, MrgX2 is resistant 
to agonist-induced receptor phosphorylation, desensitization and internalization 
(63). This study evaluated the localization of MrgX2 before and after stimulation 
with the basic secretagogue CST. IF experiments were performed on RBL-2H3 
cells transiently expressing HA- tagged MrgX2 using anti-HA antibody for the 
detection of MrgX2.  
 
As shown in Figure 15, MrgX2 is present on the plasma membrane as well as the 
cytoplasm. On stimulation with CST, the receptor remained on the plasma 
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membrane as well as in the cytoplasm but with a more peri-nuclear and punctate 
appearance. 
 
4.5 Effects of LL-37 and SP-induced degranulation on RBL-2H3 cells stably 
expressing MrgX2  
Excessive production of LL-37 as well as dysregulation of MC activity have been 
implicated in the pathogenesis of rosacea (118, 125). In both rosacea and AD, 
MCs are able to maintain neurogenic inflammation through activation by 
neuropeptides such as SP (131, 163). MrgX2 has been shown to function as a 
binding site for a wide range of unrelated basic peptides including SP and LL-37, 
leading to the degranulation of MCs (63, 64). Therefore, our goal was to show 
that ectopic expression of MrgX2 in RBL-2H3 cells makes these cells responsive 
to LL-37 and SP resulting in degranulation. It should be noted that without 
transfection of the corresponding cDNA encoding the receptor, RBL-2H3 cells do 
not endogenously express MrgX2 and are unresponsive to LL-37 and SP-
induced degranulation.  As shown in Fig. 16, stimulation by LL-37 and SP 
induced dose-dependent degranulation in RBL-2H3 cells stably expressing 
MrgX2. 
 
4.6 Expression of MrgX2 in humanized mouse lung tissues 
Very few MCs are present in the mouse bronchioles and lung parenchyma. 
However, engraftment of human HSCs into severely immune deficient mice 
transgenic for human cytokines (humanized mice) leads to the development of 
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human MCs in mouse tissues (159). The possibility that these mice develop 
human MCs in mouse lung and if they express MrgX2 have not been determined. 
First, we used NSG-SGM3 mice preconditioned with busulfan before engraftment 
of human HSCs. Our IHC study with tryptase antibody demonstrated that human 
MCs develop in the lung of humanized mice (Fig. 17A). We used IF analysis to 
determine if these MCs express MrgX2. As shown in Fig. 17B, MrgX2 is 
expressed in the lung of humanized mice and this receptor is expressed on 
human MCs. Similar results were obtained with NSG-SGM3 preconditioned by 
irradiation before engraftment of human HSCs (Fig 18 A and B).  
 
5. DISCUSSION 
Mrg receptors belong to the GPCR family. In humans, four MrgX genes, MrgX1 – 
MrgX4 have been identified while mice have 32 Mrg coding genes (60). As a 
result, human and mice Mrg receptors share only 45-65% amino acid sequence 
identity (64). Studies have shown that a wide variety of biologically relevant 
cationic peptides including neuropeptides and AMPs induce dose-dependent 
degranulation of MCs via MrgX2 (32, 63, 64). To the best of our knowledge, 
expression of MrgX2 has been reported only in dorsal root ganglia and MCs (64, 
65, 69). Given the recent report that expression of MrgX2 on MCs is upregulated 
in skin of patients with severe chronic urticaria, we hypothesized that MrgX2 is 
also expressed on human lung and gingival MCs. We further hypothesized that 
its expression will be increased in AD, rosacea, CP and asthma.  
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MCs are granule containing immune cells with varied functions in both health and 
disease. They are more abundant at sites that are continuously exposed to the 
external environment and are usually located beneath the epithelium adjacent to 
blood vessels and in proximity to nerve fibers (4). In the physiological state, MCs 
are key players in promoting innate immunity and host defense against various 
pathogens (6, 56). They are also involved in maintaining normal homeostasis as 
well as angiogenesis and wound healing (5, 44). In the adaptive immune 
response, MCs play a role in regulating the development of B cells as well as the 
differentiation of naïve T cells (20, 21). MCs interact with AMPs and 
neuropeptides. hBDs and LL-37 induce Ca2+ mobilization, chemotaxis and 
degranulation in MCs resulting in the release of mediators (32). Neuropeptides 
such as VIP, CGRP and SP released by nerve terminals also activate MCs 
leading to degranulation. 
 
Under physiological conditions the skin and gingiva are constantly exposed to 
pathogens. hBDs and LL-37 are potent AMPs produced by activated epithelial 
cells and neutrophils respectively (30). They exhibit antimicrobial properties 
against a wide variety of microorganisms. hBDs are produced by epithelial cells 
in response to exposure to infectious agents which they kill by binding to 
negatively charged phospholipid residues on their membrane thereby forming 
pores (164). Since hBDs activate MCs via MrgX2, this raises the interesting 
possibility that upon exposure to pathogens, epithelial cells produce hBDs, which 
activate MCs resulting in the secretion of MC-mediators. MC degranulation and 
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release of mediators such as histamine leads to increased vascular permeability 
and promotes the recruitment of leucocytes, which contribute to microbial killing 
by phagocytosis (165). Furthermore, the recruited neutrophils release LL-37, 
which also activate MCs via MrgX2 thereby contributing to host defense through 
activation of more MCs and recruitment of more neutrophils. Therefore, it 
appears that MrgX2 expressed on MCs facilitates vascular permeability and 
neutrophil recruitment and plays a central role in orchestrating host defense by 
functioning as an important link between the epithelium and neutrophils. 
Interestingly, AMPs and MCs are both involved in modulating the immune 
system, angiogenesis and wound healing (23, 166, 167). The skin, which is 
highly innervated, is also continuously exposed to external stimuli during the 
physiological state. The neuropeptide SP released by nerve endings in response 
to physical and emotional stimuli activate MCs via MrgX2 with the resultant effect 
of increased vascular permeability and granulocyte infiltration. 
 
MCs play important roles in host defense and wound healing but their 
inappropriate activation leads to allergic and inflammatory disease. MCs are 
known to be involved in chronic inflammatory conditions, which involve AMPs 
and neuropeptides. Therefore, in disease conditions such AD, rosacea, CP and 
asthma MC activation leads to undesirable clinical manifestations. 
 
This study has demonstrated that MCs in both healthy and diseased skin express 
MrgX2. In the skin of patients diagnosed with AD, the number of MCs was not 
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significantly different compared to control subjects. Also, there was no difference 
in the expression of MrgX2 by MrgX2-positive MCs between the groups. The 
results may be explained by the fact that in healthy conditions, MCTC, which are 
known to express MrgX2 are prominent in the skin and so do not need to be 
recruited to the skin in AD. It is more likely generation of ligands such as SP and 
MBP secreted from recruited eosinophils contribute to the symptoms associated 
with AD via the activation of MrgX2 expressed in MCs. It is noteworthy that the 
control skin samples used in our study were taken from scar tissue and MCs are 
known to play a very important role in wound healing. This was done because we 
did not have access to normal human skin samples. It is therefore possible that 
the control we used had elevated number of MCs making to difficult to assess the 
MC numbers in control and AD samples. Nevertheless, the presence of MrgX2 in 
MCs of skin samples taken from AD patients suggests that MrgX2 contributes to 
the pathogenesis of AD.  
 
We also evaluated the expression of MrgX2 by MCs in the skin of patients with 
rosacea, which is a chronic inflammatory skin disorder that involves MCs and 
found that these MCs express MrgX2. Furthermore, we compared the number of 
MCs in rosacea skin with control skin and found no significant difference between 
the groups. However, there was a significant reduction in the expression of 
tryptase-positive MCs in the rosacea group, which could indicate that the 
reduced expression of tryptase by MCs in the rosacea group is due to 
degranulation of MCs. In spite of the reduced tryptase expression by MCs in the 
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rosacea group, there was no significant difference in the expression of MrgX2 by 
MrgX2-positive MCs between the groups signifying greater activity of MrgX2 in 
MCs in rosacea skin compared to control. LL-37 plays a central role in the 
pathogenesis of rosacea (118). Furthermore, increased expression of SP has 
also been reported in rosacea lesions (131). Therefore, we propose that MC 
activation and degranulation by LL-37 and SP via MrgX2 contribute to the 
pathogenesis of rosacea. 
 
The expression of MrgX2 by gingival MCs from healthy and periodontally 
involved gingiva was assessed showing that MCs from both groups express 
MrgX2. We did not evaluate differences in MC numbers due to very small sample 
size. Studies have reported increased numbers of MCs in the gingiva of patients 
with periodontal disease compared with controls and a significant correlation 
between MC density, degree of degranulation and periodontitis severity has been 
reported (132). Expression of LL-37 is increased in gingival crevicular fluid of 
patients with periodontitis and a significantly higher basal hBD3 expression in 
keratinocytes from periodontitis patients compared to controls has been reported 
(135, 136). Our finding that MrgX2 is expressed in healthy and diseased gingival 
MCs, suggests that gingival MrgX2-positive MCs contribute to host defense in 
the oral cavity via activation by AMPs. It is also possible that MrgX2 also 
contributes to CP due elevated hBD3/LL-37 and increased number of MrgX2-
expressing MCs. 
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We demonstrated that MCs in healthy and asthmatic lung express MrgX2. The 
number of MCs, MrgX2-positive cells as well as MrgX2-positive MCs were 
significantly increased in lung tissue from individuals who died from asthma 
patients compared to individuals who died from other causes. Also, an increased 
number of MCs were present in the lung smooth muscle of asthma patients 
compared with controls. This finding is consistent with previous reports that the 
number of MCTC is increased in bronchial smooth muscles of patients with 
asthma compared with controls (144, 146). It is noteworthy that MCTC express 
GPCRs for MrgX2 (147). Eosinophils and neutrophils play important roles in the 
last phase of asthma (153). Eosinophil-derived MBP as well as neutrophil-
derived LL-37 activate MCs via MrgX2 (63, 65). In children, asthma is 
exacerbated by HRV and RSV, which are both associated with increased 
induction of hBDs in bronchial epithelial cells (148). Therefore it appears that 
MCTC, which are recruited to the lungs of asthmatics, are activated by hBDs, LL-
37 and MBP via MrgX2 leading to release of mediators, which cause 
bronchospasm and exacerbates the asthma symptoms.  
 
Unlike most GPCRs that are expressed on MCs, MrgX2 is located at both 
plasma membrane and intracellular sites (65, 162). Using RBL-2H3 cells 
transiently transfected with HA-tagged MrgX2, we also obtained similar results, 
which indicate that MrgX2 ligands can activate MCs via interaction with the 
receptor at the plasma membrane and intracellular sites. Prior studies have 
shown that MrgX2 is resistant to agonist-induced receptor phosphorylation, 
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desensitization and internalization (63). Although MrgX2 remained on the plasma 
membrane and intracellularly on stimulation with CST in this study, there was a 
more punctate and peri-nuclear appearance indicating that there may be some 
mobilization of the receptor. More studies are ongoing to identify the exact 
intracellular location of the receptor before and after stimulation.  
 
MrgX2 is expressed in human but not in mouse MCs, thus making it difficult to 
target the receptor for in vivo studies. Humanized mice have recently been used 
to study the role of human MCs in vivo. However, the possibility that these MCs 
express MrgX2 has not been previously tested. We found that as for asthmatic 
human lung MCs, lung of humanized mice develop human MCs that express 
MrgX2. Preliminary studies performed by others in Dr. Ali’s lab have shown that 
human MCs develop in the skin and gingiva of humanized mice.   Therefore, 
humanized mice may be used as models to study the role of MrgX2 on host 
defense and chronic inflammatory diseases such as AD, rosacea, periodontitis 
and asthma.  
 
6. CONCLUSIONS 
MCs have various functions in both health and disease. Prior studies have shown 
that a wide range of structurally unrelated small cationic peptides including AMPs 
and neuropeptides induce dose-dependent degranulation of MCs via MrgX2 (32, 
63, 64). This study has shown that MrgX2 is expressed in healthy human skin, 
gingiva and lung tissue. This suggests that activation of MrgX2 on MCs by AMPs 
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generated by the epithelium (hBDs) and neutrophil (LL-37) plays a pivotal role in 
host defense. Currently, around 500 - 600 AMPs are in clinical development for 
the treatment of microbial infection; the mechanisms of their action include both 
antimicrobial activity and the modulation of the immune system (168). However, 
a major limitation of this strategy is that chemical synthesis of these AMPs is 
prohibitively expensive and post-synthesis modifications (cyclization, disulfide 
bonds, folding) are inadequate for optimal antimicrobial activity. Gupta et al., 
recently demonstrated that AMPs such as retrocyclin and protegrin purified from 
transgenic plant chloroplasts kill microbes directly and induce MC degranulation 
via MrgX2 (162). Thus, harnessing this dual feature of plant generated AMPs 
could facilitate their advancement to the clinic for the treatment of periodontal 
and cutaneous microbial infection overcoming major hurdles in current 
production systems.  
 
This study has demonstrated the presence of MrgX2-positive MCs in the skin of 
patients with AD and rosacea as well as gingiva tissue from CP patients. Given 
that eosinophil-derived peptides, LL-37 and hBDs are increased in AD, rosacea 
and CP respectively suggest that MrgX2 contributes to these diseases via 
increased MC degranulation. Our finding that MCs that express MrgX2 are 
upregulated in chronic asthma suggests it participates in the pathogenesis of 
asthma and may be potentially targeted for its treatment. Finally, we found that 
human MCs, which develop in the lungs of humanized mice, express MrgX2. 
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Therefore humanized mice may be used as models for future in vivo studies on 
the role of MrgX2 on host defense and chronic inflammatory diseases.  
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7. FIGURES 
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  Figure 8  
(A) Tryptase (B) MrgX2
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8. FIGURE LEGEND 
Figure 1. MCs in skin of patients with AD. IHC was performed on human skin 
tissue from (A and B) control subjects and (C and D) patients diagnosed with AD 
using the MC marker tryptase. Note dark brown cytoplasmic staining of MCs. 
Most MCs were observed in the dermal layers in both healthy and diseased skin 
tissue compared to the epidermis. 4X scale bar = 2 mm while 20X scale bar = 
200 μm.  
 
Figure 2. MrgX2 is expressed in skin MCs of normal subjects and patients 
with AD. IF was performed on human skin tissue from  (A and B) control 
subjects and (C and D) AD patients. MrgX2 is shown in red, tryptase in green 
and the nuclei blue. Note that there is a greater degree of colocalization in AD 
compared with normal. Images taken at 40X magnification using a Nikon Eclipse 
fluorescent microscope. Scale bar = 50μm. 
 
Figure 3. MC number in normal and AD skin. Skin samples from 3 patients 
diagnosed with AD and 3 control patients were analyzed using IF. Pictures were 
taken from 5 randomly selected visual fields in each skin sample at a 
magnification of 40X. Image exposure, size and dimensions were exactly the 
same for all analyzed images. The number of skin MCs was not significantly 
different in skin of AD patients compared with control subjects.  
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Figure 4. Intensity of MrgX2 expression by MCs in AD. Using colocalized IF 
images, the intensity of the green tryptase staining by MCs as well as red MrgX2 
staining in the same MCs was measured using Metamorph image analysis 
software. Image exposure was exactly the same for all analyzed images. The 
intensity of tryptase expression by MCs was not significantly different in skin 
tissues from control subjects compared with AD patients. There was also no 
significant difference in the intensity of MrgX2 expression by MCs between the 2 
groups.  
 
Figure 5. MCs in skin of patients with rosacea. IHC was performed on human 
skin tissue from (A and B) control subjects and (C and D) patients diagnosed with 
rosacea using the MC marker tryptase. Note dark brown cytoplasmic staining of 
MCs. Most MCs were observed in the dermal layers in both healthy and diseased 
skin tissue compared to the epidermis. 4X scale bar = 2 mm while 20X scale bar 
= 200 μm.  
 
Figure 6. MrgX2 is expressed in skin MCs of normal subjects and patients 
with rosacea. IF was performed on human skin tissue from  (A and B) control 
subjects and (C and D) rosacea patients. MrgX2 is shown in red, tryptase in 
green and the nuclei blue. Note that there is a greater degree of colocalization in 
rosacea compared with normal. Images taken at 40X magnification using a Nikon 
Eclipse fluorescent microscope. Scale bar = 50μm. 
 78 
Figure 7. MC number in normal and rosacea skin. Skin samples from 2 
patients diagnosed with rosacea and 3 control patients were analyzed using IF. 
Pictures were taken from 5 randomly selected visual fields in each skin sample at 
a magnification of 40X. Image exposure, size and dimensions were exactly the 
same for all analyzed images. The number of skin MCs was not significantly 
different in skin of rosacea patients compared with control subjects.  
 
Figure 8. Intensity of MrgX2 expression by MCs in rosacea. Using 
colocalized IF images, the intensity of the green tryptase staining by MCs as well 
as red MrgX2 staining in the same MCs was measured using Metamorph image 
analysis software. Image exposure was exactly the same for all analyzed 
images. The intensity of tryptase expression by MCs was significantly reduced in 
skin tissues from rosacea patients compared with control (P = 0.0260).  However, 
there was no significant difference in the intensity of MrgX2 expression by MCs 
between the 2 groups.  
 
Figure 9. MCs in gingiva of patients with CP. IHC was performed on human 
gingiva tissue from (A and B) control subjects and (C and D) patients diagnosed 
with CP using the MC marker tryptase. Note dark brown cytoplasmic staining of 
MCs. Most of the MCs are present in the lamina propria and submucosa in both 
healthy and diseased gingiva tissue compared to the epithelium. Also note that 
gingiva samples from patients with CP have a greater number of MCs in the 
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epithelium compared to the healthy gingiva. 4X scale bar = 2 mm while 20X scale 
bar = 200 μm 
 
Figure 10. MrgX2 is expressed in gingival MCs of normal subjects and 
patients with CP. IF was performed on human gingiva tissue from  (A and B) 
control subjects and (C and D) CP patients. MrgX2 is shown in red, tryptase in 
green and the nuclei blue. Note that there is a greater degree of colocalization in 
CP gingiva compared with normal gingiva. Images taken at 40X magnification 
using a Nikon Eclipse fluorescent microscope. Scale bar = 50μm. 
 
Figure 11. MCs in lung of patients with asthma. IHC was performed on human 
lung tissue from (A and B) control subjects who died from non-asthma related 
causes and (C and D) patients who died from asthma complications using the 
MC marker tryptase. Note dark brown cytoplasmic staining of MCs. An increased 
number of MCs are present in the lung smooth muscles of asthma patients 
compared to healthy lung. 10X scale bar = 500 μm while 20X scale bar = 200 μm 
 
Figure 12. MrgX2 is expressed in lung MCs of normal subjects and patients 
with asthma. IF was performed on human lung tissue from  (A and B) control 
subjects who died from non-asthma related causes and (C and D) asthma 
patients who died from asthma complications. MrgX2 is shown in red, tryptase in 
green and the nuclei blue. Note that there is a greater degree of colocalization in 
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asthma lung compared with normal lung. Images taken at 40X magnification 
using a Nikon Eclipse fluorescent microscope. Scale bar = 50μm. 
 
Figure 13. MC number in normal and asthma lung. Lung tissue from 6 
patients who died from asthma-related complications and 6 control patients who 
died from non-asthma related causes were analyzed using IF. Pictures were 
taken from 3 randomly selected visual fields in each sample at a magnification of 
20X. Image exposure, size and dimensions were exactly the same for all 
analyzed images. The number of lung MCs was significantly greater in lung 
tissue from patients who died from asthma complications compared with control 
subjects (P= 0.0178). The number of MrgX2-positive cells was also significantly 
greater in lung tissue from patients who died from asthma complications 
compared with control subjects (P= 0.0211). In both healthy and asthmatic lungs, 
a proportion of MrgX2-positive cells were not MCs. 
 
Figure 14. Number of MrgX2-positive MCs in normal and asthma lung. 
Image analysis was performed as in Fig. 13. The number of MrgX2-positive MCs 
was significantly greater in lung tissue from patients who died from asthma 
complications compared with control subjects (P=0.0176). 
 
Figure 15. MrgX2 localization in RBL-2H3 cells transiently expressing HA- 
tagged MrgX2. IF analysis was performed on RBL-2H3 cells transiently 
expressing HA- tagged MrgX2 before and after stimulation with CST using anti-
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HA antibody for the detection of MrgX2.  Prior to stimulation with CST, MrgX2 is 
diffusely expressed on the plasma membrane as well as the cytoplasm. On 
stimulation with CST, the receptor remained on the plasma membrane as well as 
in the cytoplasm but with a more peri-nuclear and punctate appearance. Images 
taken at 20X magnification using a Nikon Eclipse fluorescent microscope. Scale 
bar = 100μm. 
 
Figure 16. Effects of LL-37 and SP-induced degranulation on RBL-2H3 cells 
stably expressing MrgX2. RBL-2H3 cells stably expressing MrgX2 were 
exposed to buffer (control), LL-37 at 5μM and 10μM and SP at 5μM and 10μM. 
Percentage degranulation (β-hexosaminidase release) was determined. Data are 
Mean ± SEM of 3 experiments. 
 
Figure 17. Human MCs in the lung of NSG-SGM3 mice preconditioned with 
busulfan express MrgX2. IHC performed with tryptase antibody demonstrates 
that human MCs develop in the lung of humanized mice preconditioned with 
busulfan (Fig. 17A). IF was also performed on the humanized mice lung tissue 
(Fig. 17B). MrgX2 is shown in red, tryptase in green and the nuclei blue. Images 
taken at 40X magnification using a Nikon Eclipse fluorescent microscope. Scale 
bar = 50μm. 
 
Figure 18. Human MCs in the lung of NSG-SGM3 mice preconditioned by 
irradiation express MrgX2. IHC performed with tryptase antibody demonstrates 
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that human MCs develop in the lung of humanized mice preconditioned by 
irradiation (Fig. 18A). IF was also performed on the humanized mice lung tissue 
(Fig. 18B). MrgX2 is shown in red, tryptase in green and the nuclei blue. Images 
taken at 40X magnification using a Nikon Eclipse fluorescent microscope. Scale 
bar = 50μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 83 
9. BIBLIOGRAPHY 
 
1. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as 
positive, regulators of immunity. Nat Rev Immunol. 2008 Jun;8(6):478-86. 
2. Sismanopoulos N, Delivanis DA, Alysandratos KD, Angelidou A, Therianou A, Kalogeromitros 
D, et al. Mast cells in allergic and inflammatory diseases. Curr Pharm Des. 2012;18(16):2261-77. 
3. Cruse G, Bradding P. Mast cells in airway diseases and interstitial lung disease. Eur J 
Pharmacol. 2015 May 8. 
4. Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in 
innate and adaptive immunity. Eur J Immunol. 2010 Jul;40(7):1843-51. 
5. Weller CL, Collington SJ, Williams T, Lamb JR. Mast cells in health and disease. Clin Sci 
(Lond). 2011 Jun;120(11):473-84. 
6. Bachelet I, Levi-Schaffer F, Mekori YA. Mast cells: not only in allergy. Immunol Allergy Clin 
North Am. 2006 Aug;26(3):407-25. 
7. Olivera A, Rivera J. Paradigm shifts in mast cell and basophil biology and function: an 
emerging view of immune regulation in health and disease. Methods Mol Biol. 2014;1192:3-31. 
8. Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, et 
al. Mast cells and inflammation. Biochim Biophys Acta. 2012 Jan;1822(1):21-33. 
9. Reber LL, Sibilano R, Mukai K, Galli SJ. Potential effector and immunoregulatory functions of 
mast cells in mucosal immunity. Mucosal Immunol. 2015 May;8(3):444-63. 
10. Amin K. The role of mast cells in allergic inflammation. Respir Med. 2012 Jan;106(1):9-14. 
11. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells 
that have distinct neutral protease compositions. Proc Natl Acad Sci U S A. 1986 
Jun;83(12):4464-8. 
12. Schwartz LB. Mast cells: function and contents. Curr Opin Immunol. 1994 Feb;6(1):91-7. 
13. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as 
"tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 
2005;23:749-86. 
14. Broide DH, Finkelman F, Bochner BS, Rothenberg ME. Advances in mechanisms of asthma, 
allergy, and immunology in 2010. J Allergy Clin Immunol. 2011 Mar;127(3):689-95. 
15. Kalesnikoff J, Galli SJ. Anaphylaxis: mechanisms of mast cell activation. Chem Immunol 
Allergy. 2010;95:45-66. 
16. Moon TC, St Laurent CD, Morris KE, Marcet C, Yoshimura T, Sekar Y, et al. Advances in 
mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol. 2010 
Mar;3(2):111-28. 
 84 
17. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 
2010 Jun;10(6):440-52. 
18. Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev. 2000 Feb;173:131-40. 
19. Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin 
Immunol. 2007 Feb;19(1):31-8. 
20. Mekori YA, Metcalfe DD. Mast cell-T cell interactions. J Allergy Clin Immunol. 1999 Sep;104(3 
Pt 1):517-23. 
21. Tkaczyk C, Frandji P, Botros HG, Poncet P, Lapeyre J, Peronet R, et al. Mouse bone marrow-
derived mast cells and mast cell lines constitutively produce B cell growth and differentiation 
activities. J Immunol. 1996 Aug 15;157(4):1720-8. 
22. Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF 
promotes dendritic cell migration. J Immunol. 2006 Apr 1;176(7):4102-12. 
23. Noli C, Miolo A. The mast cell in wound healing. Vet Dermatol. 2001 Dec;12(6):303-13. 
24. Frandji P, Oskeritzian C, Cacaraci F, Lapeyre J, Peronet R, David B, et al. Antigen-dependent 
stimulation by bone marrow-derived mast cells of MHC class II-restricted T cell hybridoma. J 
Immunol. 1993 Dec 1;151(11):6318-28. 
25. Frandji P, Tkaczyk C, Oskeritzian C, David B, Desaymard C, Mecheri S. Exogenous and 
endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. Eur J 
Immunol. 1996 Oct;26(10):2517-28. 
26. Malaviya R, Twesten NJ, Ross EA, Abraham SN, Pfeifer JD. Mast cells process bacterial Ags 
through a phagocytic route for class I MHC presentation to T cells. J Immunol. 1996 Feb 
15;156(4):1490-6. 
27. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. 
Pharmacol Rev. 2003 Mar;55(1):27-55. 
28. Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T, et al. An angiogenic role 
for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003 Jun;111(11):1665-72. 
29. Bowdish DM, Davidson DJ, Hancock RE. Immunomodulatory properties of defensins and 
cathelicidins. Curr Top Microbiol Immunol. 2006;306:27-66. 
30. Weinberg A, Jin G, Sieg S, McCormick TS. The yin and yang of human Beta-defensins in 
health and disease. Front Immunol. 2012 Oct 8;3:294. 
31. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol. 2002 Feb;14(1):96-
102. 
32. Subramanian H, Gupta K, Lee D, Bayir AK, Ahn H, Ali H. beta-Defensins activate human 
mast cells via Mas-related gene X2. J Immunol. 2013 Jul 1;191(1):345-52. 
 85 
33. Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL. Control of the innate epithelial 
antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. 
Immunology. 2006 Aug;118(4):509-19. 
34. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide 
antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) 
production from mast cells. Eur J Immunol. 2001 Apr;31(4):1066-75. 
35. Schiemann F, Brandt E, Gross R, Lindner B, Mittelstadt J, Sommerhoff CP, et al. The 
cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-
regulation by CXCL4. J Immunol. 2009 Aug 15;183(4):2223-31. 
36. Niyonsaba F, Ushio H, Hara M, Yokoi H, Tominaga M, Takamori K, et al. Antimicrobial 
peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic 
cytokine IL-31 by human mast cells. J Immunol. 2010 Apr 1;184(7):3526-34. 
37. Soruri A, Grigat J, Forssmann U, Riggert J, Zwirner J. beta-Defensins chemoattract 
macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur J 
Immunol. 2007 Sep;37(9):2474-86. 
38. Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I. Epithelial cell-derived human 
beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and 
phospholipase C-dependent pathway. Int Immunol. 2002 Apr;14(4):421-6. 
39. Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, Ogawa H, et al. A cathelicidin 
family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology. 2002 
May;106(1):20-6. 
40. Chen X, Niyonsaba F, Ushio H, Hara M, Yokoi H, Matsumoto K, et al. Antimicrobial peptides 
human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular 
permeability. Eur J Immunol. 2007 Feb;37(2):434-44. 
41. Bienenstock J, MacQueen G, Sestini P, Marshall JS, Stead RH, Perdue MH. Mast cell/nerve 
interactions in vitro and in vivo. Am Rev Respir Dis. 1991 Mar;143(3 Pt 2):S55-8. 
42. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1997 Oct;77(4):1033-79. 
43. Pundir P, Kulka M. The role of G protein-coupled receptors in mast cell activation by 
antimicrobial peptides: is there a connection? Immunol Cell Biol. 2010 Aug;88(6):632-40. 
44. Gilfillan AM, Beaven MA. Regulation of mast cell responses in health and disease. Crit Rev 
Immunol. 2011;31(6):475-529. 
45. Okayama Y, Ono Y, Nakazawa T, Church MK, Mori M. Human skin mast cells produce TNF-
alpha by substance P. Int Arch Allergy Immunol. 1998 Sep;117 Suppl 1:48-51. 
46. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate 
human mast cell degranulation and chemokine production. Immunology. 2008 Mar;123(3):398-
410. 
47. Erjavec F, Lembeck F, Florjanc-Irman T, Skofitsch G, Donnerer J, Saria A, et al. Release of 
histamine by substance P. Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):67-70. 
 86 
48. Lowman MA, Benyon RC, Church MK. Characterization of neuropeptide-induced histamine 
release from human dispersed skin mast cells. Br J Pharmacol. 1988 Sep;95(1):121-30. 
49. Grundemar L, Hakanson R. Neuropeptide Y, peptide YY and C-terminal fragments release 
histamine from rat peritoneal mast cells. Br J Pharmacol. 1991 Dec;104(4):776-8. 
50. Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, et al. What is 
the physiological function of mast cells? Exp Dermatol. 2003 Dec;12(6):886-910. 
51. Artuc M, Hermes B, Steckelings UM, Grutzkau A, Henz BM. Mast cells and their mediators in 
cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol. 1999 
Feb;8(1):1-16. 
52. Meininger CJ, Zetter BR. Mast cells and angiogenesis. Semin Cancer Biol. 1992 Apr;3(2):73-
9. 
53. Clark RA. Biology of dermal wound repair. Dermatol Clin. 1993 Oct;11(4):647-66. 
54. Woodley DT, Chen JD, Kim JP, Sarret Y, Iwasaki T, Kim YH, et al. Re-epithelialization. 
Human keratinocyte locomotion. Dermatol Clin. 1993 Oct;11(4):641-6. 
55. Moulin V. Growth factors in skin wound healing. Eur J Cell Biol. 1995 Sep;68(1):1-7. 
56. Rao KN, Brown MA. Mast cells: multifaceted immune cells with diverse roles in health and 
disease. Ann N Y Acad Sci. 2008 Nov;1143:83-104. 
57. Maurer M, Paus R, Czarnetzki BM. Mast cells as modulators of hair follicle cycling. Exp 
Dermatol. 1995 Aug;4(4 Pt 2):266-71. 
58. Silberstein R, Melnick M, Greenberg G, Minkin C. Bone remodeling in W/Wv mast cell 
deficient mice. Bone. 1991;12(4):227-36. 
59. Nagasaka A, Matsue H, Matsushima H, Aoki R, Nakamura Y, Kambe N, et al. Osteopontin is 
produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J 
Immunol. 2008 Feb;38(2):489-99. 
60. Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in 
specific subsets of nociceptive sensory neurons. Cell. 2001 Sep 7;106(5):619-32. 
61. Lembo PM, Grazzini E, Groblewski T, O'Donnell D, Roy MO, Zhang J, et al. Proenkephalin A 
gene products activate a new family of sensory neuron--specific GPCRs. Nat Neurosci. 2002 
Mar;5(3):201-9. 
62. Subramanian H, Kashem SW, Collington SJ, Qu H, Lambris JD, Ali H. PMX-53 as a dual 
CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells. Mol 
Pharmacol. 2011 Jun;79(6):1005-13. 
63. Subramanian H, Gupta K, Guo Q, Price R, Ali H. Mas-related gene X2 (MrgX2) is a novel G 
protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: resistance to 
receptor phosphorylation, desensitization, and internalization. J Biol Chem. 2011 Dec 
30;286(52):44739-49. 
 87 
64. Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, Furuno M, et al. Immunoglobulin E-
independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res 
Commun. 2006 Nov 3;349(4):1322-8. 
65. Fujisawa D, Kashiwakura J, Kita H, Kikukawa Y, Fujitani Y, Sasaki-Sakamoto T, et al. 
Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with 
severe chronic urticaria. J Allergy Clin Immunol. 2014 Sep;134(3):622,633.e9. 
66. Ferry X, Brehin S, Kamel R, Landry Y. G protein-dependent activation of mast cell by 
peptides and basic secretagogues. Peptides. 2002 Aug;23(8):1507-15. 
67. Hernanz A, Muelas G, Borbujo J. Plasma neuropeptide pattern in acute idiopathic urticaria. Int 
Arch Allergy Appl Immunol. 1989;90(2):198-200. 
68. Smith CH, Atkinson B, Morris RW, Hayes N, Foreman JC, Lee TH. Cutaneous responses to 
vasoactive intestinal polypeptide in chronic idiopathic urticaria. Lancet. 1992 Jan 
11;339(8785):91-3. 
69. Robas N, Mead E, Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal 
root ganglion. J Biol Chem. 2003 Nov 7;278(45):44400-4. 
70. Kashem SW, Subramanian H, Collington SJ, Magotti P, Lambris JD, Ali H. G protein coupled 
receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: 
roles of Mas-related genes MrgX1 and MrgX2. Eur J Pharmacol. 2011 Oct 1;668(1-2):299-304. 
71. Okayama Y, Saito H, Ra C. Targeting human mast cells expressing g-protein-coupled 
receptors in allergic diseases. Allergol Int. 2008 Sep;57(3):197-203. 
72. McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. Identification of a mast-
cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015 Mar 
12;519(7542):237-41. 
73. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev 
Biochem. 1998;67:653-92. 
74. Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in G protein-coupled 
receptor regulation. Annu Rev Pharmacol Toxicol. 1998;38:289-319. 
75. Langkabel P, Zwirner J, Oppermann M. Ligand-induced phosphorylation of anaphylatoxin 
receptors C3aR and C5aR is mediated by "G protein-coupled receptor kinases. Eur J Immunol. 
1999 Sep;29(9):3035-46. 
76. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009 
Jun;39(6):777-87. 
77. Ferrer M, Nunez-Cordoba JM, Luquin E, Grattan CE, De la Borbolla JM, Sanz ML, et al. 
Serum total tryptase levels are increased in patients with active chronic urticaria. Clin Exp Allergy. 
2010 Dec;40(12):1760-6. 
78. Tidman MJ. Managing urticaria in primary care. Practitioner. 2015 Feb;259(1779):25,8, 3. 
 88 
79. Metz M, Krull C, Hawro T, Saluja R, Groffik A, Stanger C, et al. Substance P is upregulated in 
the serum of patients with chronic spontaneous urticaria. J Invest Dermatol. 2014 
Nov;134(11):2833-6. 
80. Borici-Mazi R, Kouridakis S, Kontou-Fili K. Cutaneous responses to substance P and 
calcitonin gene-related peptide in chronic urticaria: the effect of cetirizine and dimethindene. 
Allergy. 1999 Jan;54(1):46-56. 
81. Peters MS, Schroeter AL, Kephart GM, Gleich GJ. Localization of eosinophil granule major 
basic protein in chronic urticaria. J Invest Dermatol. 1983 Jul;81(1):39-43. 
82. Piliponsky AM, Gleich GJ, Nagler A, Bar I, Levi-Schaffer F. Non-IgE-dependent activation of 
human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and 
modulated by the membrane form of stem cell factor. Blood. 2003 Mar 1;101(5):1898-904. 
83. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune 
dysregulation. Immunol Rev. 2011 Jul;242(1):233-46. 
84. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. 
Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of 
Allergology and Clinical Immunology/American Academy of Allergy, Asthma and 
Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006 Jul;118(1):152-69. 
85. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines 
of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic 
dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338-51. 
86. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66 
Suppl 1:8-16. 
87. Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483-94. 
88. Wen HJ, Chen PC, Chiang TL, Lin SJ, Chuang YL, Guo YL. Predicting risk for early infantile 
atopic dermatitis by hereditary and environmental factors. Br J Dermatol. 2009 Nov;161(5):1166-
72. 
89. Schultz Larsen FV, Holm NV. Atopic dermatitis in a population based twin series. 
Concordance rates and heritability estimation. Acta Derm Venereol Suppl (Stockh). 
1985;114:159. 
90. Mu Z, Zhao Y, Liu X, Chang C, Zhang J. Molecular biology of atopic dermatitis. Clin Rev 
Allergy Immunol. 2014 Oct;47(2):193-218. 
91. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic 
diseases. N Engl J Med. 2011 Oct 6;365(14):1315-27. 
92. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-
function variants of the epidermal barrier protein filaggrin are a major predisposing factor for 
atopic dermatitis. Nat Genet. 2006 Apr;38(4):441-6. 
93. Wollenberg A, Seba A, Antal AS. Immunological and molecular targets of atopic dermatitis 
treatment. Br J Dermatol. 2014 Jul;170 Suppl 1:7-11. 
 89 
94. Man MQ, Hatano Y, Lee SH, Man M, Chang S, Feingold KR, et al. Characterization of a 
hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, 
and biochemical changes following single versus multiple oxazolone challenges. J Invest 
Dermatol. 2008 Jan;128(1):79-86. 
95. Mihm MC,Jr, Soter NA, Dvorak HF, Austen KF. The structure of normal skin and the 
morphology of atopic eczema. J Invest Dermatol. 1976 Sep;67(3):305-12. 
96. Irani AM, Sampson HA, Schwartz LB. Mast cells in atopic dermatitis. Allergy. 1989;44 Suppl 
9:31-4. 
97. Soter NA. Morphology of atopic eczema. Allergy. 1989;44 Suppl 9:16-9. 
98. Sugiura H, Hirota Y, Uehara M. Heterogeneous distribution of mast cells in lichenified lesions 
of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:115-8. 
99. Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev 
Allergy Immunol. 2011 Dec;41(3):298-310. 
100. Terada M, Tsutsui H, Imai Y, Yasuda K, Mizutani H, Yamanishi K, et al. Contribution of IL-18 
to atopic-dermatitis-like skin inflammation induced by Staphylococcus aureus product in mice. 
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8816-21. 
101. Ong PY, Leung DY. Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep. 
2006 Sep;6(5):384-9. 
102. Horsmanheimo L, Harvima IT, Jarvikallio A, Harvima RJ, Naukkarinen A, Horsmanheimo M. 
Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol. 1994 
Sep;131(3):348-53. 
103. Obara W, Kawa Y, Ra C, Nishioka K, Soma Y, Mizoguchi M. T cells and mast cells as a 
major source of interleukin-13 in atopic dermatitis. Dermatology. 2002;205(1):11-7. 
104. Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS. Roles of TH1 and TH2 cytokines 
in a murine model of allergic dermatitis. J Clin Invest. 1999 Apr;103(8):1103-11. 
105. Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain 
Behav Immun. 2002 Dec;16(6):622-53. 
106. Jarvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic 
dermatitis and nummular eczema. Arch Dermatol Res. 2003 Apr;295(1):2-7. 
107. Salomon J, Baran E. The role of selected neuropeptides in pathogenesis of atopic 
dermatitis. J Eur Acad Dermatol Venereol. 2008 Feb;22(2):223-8. 
108. Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis--eosinophil granule 
proteins as markers of disease activity. Allergy. 1993 Jan;48(1):1-5. 
109. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol. 1989;69(5):419-
23. 
 90 
110. Feldman SR, Huang WW, Huynh TT. Current drug therapies for rosacea: a chronic vascular 
and inflammatory skin disease. J Manag Care Spec Pharm. 2014 Jun;20(6):623-9. 
111. Doe PT, Asiedu A, Acheampong JW, Rowland Payne CM. Skin diseases in Ghana and the 
UK. Int J Dermatol. 2001 May;40(5):323-6. 
112. Khaled A, Hammami H, Zeglaoui F, Tounsi J, Zermani R, Kamoun MR, et al. Rosacea: 244 
Tunisian cases. Tunis Med. 2010 Aug;88(8):597-601. 
113. Del Rosso JQ. Management of cutaneous rosacea: emphasis on new medical therapies. 
Expert Opin Pharmacother. 2014 Oct;15(14):2029-38. 
114. Wollina U. Recent advances in the understanding and management of rosacea. F1000Prime 
Rep. 2014 Jul 8;6:50,50. eCollection 2014. 
115. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, 
pathogenesis, and risk factors. J Am Acad Dermatol. 2015 May;72(5):749,58; quiz 759-60. 
116. Heiberger K, Brenman S. Common triggers of facial erythema in adults. JAAPA. 2001 
Sep;14(9):49,50, 53-4. 
117. Landow K. Unraveling the mystery of rosacea. Keys to getting the red out. Postgrad Med. 
2002 Dec;112(6):51,8, 82; quiz 9. 
118. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J 
Investig Dermatol Symp Proc. 2011 Dec;15(1):12-5. 
119. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine 
protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007 
Aug;13(8):975-80. 
120. Schauber J, Gallo RL. The vitamin D pathway: a new target for control of the skin's immune 
response? Exp Dermatol. 2008 Aug;17(8):633-9. 
121. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, et al. Kallikrein-
mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 2006 
Oct;20(12):2068-80. 
122. Meyer-Hoffert U, Schroder JM. Epidermal proteases in the pathogenesis of rosacea. J 
Investig Dermatol Symp Proc. 2011 Dec;15(1):16-23. 
123. Larrick JW, Hirata M, Zhong J, Wright SC. Anti-microbial activity of human CAP18 peptides. 
Immunotechnology. 1995 May;1(1):65-72. 
124. Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, et al. TLR2 
expression is increased in rosacea and stimulates enhanced serine protease production by 
keratinocytes. J Invest Dermatol. 2011 Mar;131(3):688-97. 
125. Aroni K, Tsagroni E, Kavantzas N, Patsouris E, Ioannidis E. A study of the pathogenesis of 
rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. 
Arch Dermatol Res. 2008 Mar;300(3):125-31. 
 91 
126. Schwab VD, Sulk M, Seeliger S, Nowak P, Aubert J, Mess C, et al. Neurovascular and 
neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011 
Dec;15(1):53-62. 
127. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by 
expression of cathelicidin antimicrobial peptide. J Immunol. 2003 Mar 1;170(5):2274-8. 
128. Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key 
mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014 
Nov;134(11):2728-36. 
129. Jang YH, Sim JH, Kang HY, Kim YC, Lee ES. Immunohistochemical expression of matrix 
metalloproteinases in the granulomatous rosacea compared with the non-granulomatous 
rosacea. J Eur Acad Dermatol Venereol. 2011 May;25(5):544-8. 
130. Wollina U. Rhinophyma--unusual expression of simple-type keratins and S100A in 
sebocytes and abundance of VIP receptor-positive dermal cells. Histol Histopathol. 1996 
Jan;11(1):111-5. 
131. Kurkcuoglu N, Alaybeyi F. Substance P immunoreactivity in rosacea. J Am Acad Dermatol. 
1991 Oct;25(4):725-6. 
132. Huang S, Lu F, Chen Y, Huang B, Liu M. Mast cell degranulation in human periodontitis. J 
Periodontol. 2013 Feb;84(2):248-55. 
133. Batista AC, Rodini CO, Lara VS. Quantification of mast cells in different stages of human 
periodontal disease. Oral Dis. 2005 Jul;11(4):249-54. 
134. Lagdive SS, Lagdive SB, Mani A, Anarthe R, Pendyala G, Pawar B, et al. Correlation of 
mast cells in periodontal diseases. J Indian Soc Periodontol. 2013 Jan;17(1):63-7. 
135. Liu J, Chen J, Du X, Hu L, Chen L. The expression of hBDs in the gingival tissue and 
keratinocytes from healthy subjects and periodontitis patients. Arch Oral Biol. 2014 
Feb;59(2):193-8. 
136. Puklo M, Guentsch A, Hiemstra PS, Eick S, Potempa J. Analysis of neutrophil-derived 
antimicrobial peptides in gingival crevicular fluid suggests importance of cathelicidin LL-37 in the 
innate immune response against periodontogenic bacteria. Oral Microbiol Immunol. 2008 
Aug;23(4):328-35. 
137. Turkoglu O, Emingil G, Kutukculer N, Atilla G. Gingival crevicular fluid levels of cathelicidin 
LL-37 and interleukin-18 in patients with chronic periodontitis. J Periodontol. 2009 Jun;80(6):969-
76. 
138. Lei Y, Gregory JA, Nilsson GP, Adner M. Insights into mast cell functions in asthma using 
mouse models. Pulm Pharmacol Ther. 2013 Oct;26(5):532-9. 
139. Ali H, Panettieri RA,Jr. Anaphylatoxin C3a receptors in asthma. Respir Res. 2005 Feb 
21;6:19. 
140. Maddox L, Schwartz DA. The pathophysiology of asthma. Annu Rev Med. 2002;53:477-98. 
 92 
141. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006 Jun 
22;354(25):2689-95. 
142. Oskeritzian CA, Zhao W, Min HK, Xia HZ, Pozez A, Kiev J, et al. Surface CD88 functionally 
distinguishes the MCTC from the MCT type of human lung mast cell. J Allergy Clin Immunol. 
2005 Jun;115(6):1162-8. 
143. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell 
infiltration of airway smooth muscle in asthma. N Engl J Med. 2002 May 30;346(22):1699-705. 
144. Balzar S, Fajt ML, Comhair SA, Erzurum SC, Bleecker E, Busse WW, et al. Mast cell 
phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research 
Program. Am J Respir Crit Care Med. 2011 Feb 1;183(3):299-309. 
145. Balzar S, Chu HW, Strand M, Wenzel S. Relationship of small airway chymase-positive mast 
cells and lung function in severe asthma. Am J Respir Crit Care Med. 2005 Mar 1;171(5):431-9. 
146. Andersson CK, Bergqvist A, Mori M, Mauad T, Bjermer L, Erjefalt JS. Mast cell-associated 
alveolar inflammation in patients with atopic uncontrolled asthma. J Allergy Clin Immunol. 2011 
Apr;127(4):905,12.e1-7. 
147. Kajiwara N, Sasaki T, Bradding P, Cruse G, Sagara H, Ohmori K, et al. Activation of human 
mast cells through the platelet-activating factor receptor. J Allergy Clin Immunol. 2010 
May;125(5):1137,1145.e6. 
148. Busse WW, Lemanske RF,Jr, Gern JE. Role of viral respiratory infections in asthma and 
asthma exacerbations. Lancet. 2010 Sep 4;376(9743):826-34. 
149. Duits LA, Nibbering PH, van Strijen E, Vos JB, Mannesse-Lazeroms SP, van Sterkenburg 
MA, et al. Rhinovirus increases human beta-defensin-2 and -3 mRNA expression in cultured 
bronchial epithelial cells. FEMS Immunol Med Microbiol. 2003 Aug 18;38(1):59-64. 
150. Proud D. The role of defensins in virus-induced asthma. Curr Allergy Asthma Rep. 2006 
Feb;6(1):81-5. 
151. Kota S, Sabbah A, Chang TH, Harnack R, Xiang Y, Meng X, et al. Role of human beta-
defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response 
against human respiratory syncytial virus. J Biol Chem. 2008 Aug 15;283(33):22417-29. 
152. Proud D, Sanders SP, Wiehler S. Human rhinovirus infection induces airway epithelial cell 
production of human beta-defensin 2 both in vitro and in vivo. J Immunol. 2004 Apr 
1;172(7):4637-45. 
153. Monteseirin J. Neutrophils and asthma. J Investig Allergol Clin Immunol. 2009;19(5):340-54. 
154. Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study human diseases. 
Curr Opin Endocrinol Diabetes Obes. 2010 Apr;17(2):120-5. 
155. Shultz LD, Brehm MA, Bavari S, Greiner DL. Humanized mice as a preclinical tool for 
infectious disease and biomedical research. Ann N Y Acad Sci. 2011 Dec;1245:50-4. 
156. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. 
Nat Rev Immunol. 2007 Feb;7(2):118-30. 
 93 
157. Choi B, Chun E, Kim M, Kim ST, Yoon K, Lee KY, et al. Human B cell development and 
antibody production in humanized NOD/SCID/IL-2Rgamma(null) (NSG) mice conditioned by 
busulfan. J Clin Immunol. 2011 Apr;31(2):253-64. 
158. Singh M, Singh P, Gaudray G, Musumeci L, Thielen C, Vaira D, et al. An improved protocol 
for efficient engraftment in NOD/LTSZ-SCIDIL-2Rgammanull mice allows HIV replication and 
development of anti-HIV immune responses. PLoS One. 2012;7(6):e38491. 
159. Kambe N, Hiramatsu H, Shimonaka M, Fujino H, Nishikomori R, Heike T, et al. Development 
of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic 
stem cells with identical distribution pattern to human body. Blood. 2004 Feb 1;103(3):860-7. 
160. Nicolini FE, Cashman JD, Hogge DE, Humphries RK, Eaves CJ. NOD/SCID mice 
engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted 
human progenitors and compromise human stem cell regeneration. Leukemia. 2004 
Feb;18(2):341-7. 
161. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, et al. AML xenograft 
efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human 
SCF, GM-CSF and IL-3. Leukemia. 2010 Oct;24(10):1785-8. 
162. Gupta K, Kotian A, Subramanian H, Daniell H, Ali H. Activation of human mast cells by 
retrocyclin and protegrin highlight their immunomodulatory and antimicrobial properties. 
Oncotarget. 2015 Oct 6;6(30):28573-87. 
163. Kubanov AA, Katunina OR, Chikin VV. Expression of Neuropeptides, Neurotrophins, and 
Neurotransmitters in the Skin of Patients with Atopic Dermatitis and Psoriasis. Bull Exp Biol Med. 
2015 Jul;159(3):318-22. 
164. Hazlett L, Wu M. Defensins in innate immunity. Cell Tissue Res. 2011 Jan;343(1):175-88. 
165. Marshall JS, Jawdat DM. Mast cells in innate immunity. J Allergy Clin Immunol. 2004 
Jul;114(1):21-7. 
166. Ramos R, Silva JP, Rodrigues AC, Costa R, Guardao L, Schmitt F, et al. Wound healing 
activity of the human antimicrobial peptide LL37. Peptides. 2011 Jul;32(7):1469-76. 
167. Duplantier AJ, van Hoek ML. The Human Cathelicidin Antimicrobial Peptide LL-37 as a 
Potential Treatment for Polymicrobial Infected Wounds. Front Immunol. 2013 Jul 3;4:143. 
168. Parachin NS, Franco OL. New edge of antibiotic development: antimicrobial peptides and 
corresponding resistance. Front Microbiol. 2014 Apr 8;5:147. 
 
 
 
 
 
 
